EndoChoice 10-K 21 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 16, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Entity Registrant Name	EndoChoice Holdings, Inc.
Entity Central Index Key	1,623,919
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding (in shares)		26,009,146
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 192,206,447

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 34,033,000	$ 13,761,000
Short-term marketable securities	33,872,000	0
Receivables, net	9,880,000	8,379,000
Inventories	17,473,000	13,637,000
Deferred income taxes	0	970,000
Prepaid expenses and other current assets	3,108,000	2,363,000
Total current assets	98,366,000	39,110,000
Long-term marketable securities	19,748,000	0
Property and equipment, net	11,523,000	9,668,000
Intangible assets, net	13,819,000	16,655,000
Goodwill	20,105,000	20,301,000
Deposits and other long-term assets	777,000	1,075,000
Total assets	164,338,000	86,809,000
Current liabilities:
Accounts payable	8,434,000	5,127,000
Accrued expenses and other current liabilities	9,203,000	8,328,000
Current portion of deferred rent	85,000	55,000
Deferred revenue	812,000	1,278,000
Total current liabilities	18,534,000	14,788,000
Long-term debt, net of discount	42,643,000	38,939,000
Deferred rent, less current portion	761,000	607,000
Deferred income taxes	2,493,000	4,147,000
Other long-term liabilities	614,000	2,089,000
Total liabilities	$ 65,045,000	$ 60,570,000
Commitments and contingencies
Redeemable members' capital	$ 0	$ 125,418,000
Stockholders’ equity/members' deficit:
Preferred stock, $0.001 par value per share; 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2015 and December 31, 2014	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 24,886,516 shares issued and outstanding at December 31, 2015; no shares issued and outstanding at December 31, 2014	26,000	0
Additional paid-in capital	257,384,000	0
Accumulated deficit	(156,549,000)	(97,165,000)
Accumulated other comprehensive loss	(1,568,000)	(2,014,000)
Total stockholders’ equity/members' deficit	99,293,000	(99,179,000)
Total liabilities and stockholders’ equity/redeemable members' capital and members' deficit	$ 164,338,000	$ 86,809,000

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	24,886,516	0
Common stock, shares outstanding (in shares)	24,886,516	0
Preferred Stock, Par or Stated Value Per Share (in usd per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
GI equipment and supplies	$ 58,454	$ 48,824	$ 38,772
GI pathology services	13,846	12,595	12,119
Net revenues	72,300	61,419	50,891
Cost of revenues:
GI equipment and supplies	43,745	33,815	21,502
GI pathology services	5,245	5,093	4,390
Cost of revenues	48,990	38,908	25,892
Gross profit	23,310	22,511	24,999
Operating expenses:
Research and development	17,288	21,702	16,617
Sales and marketing	30,367	27,660	18,148
General and administrative	23,158	16,456	11,355
Amortization of intangible assets	2,753	3,908	4,578
Operating expenses	73,566	69,726	50,698
Operating loss	(50,256)	(47,215)	(25,699)
Other income (expense):
Other income (expense)	(1,793)	(1,563)	327
Interest expense	(5,414)	(3,950)	(104)
Loss on early retirement of debt	(2,282)	0	0
Total other income (expense)	(9,489)	(5,513)	223
Net loss before income taxes	(59,745)	(52,728)	(25,476)
Income tax benefit (expense)	361	(916)	1,558
Net loss	(59,384)	(53,644)	(23,918)
Other comprehensive income (loss):
Foreign currency translation adjustments	562	(5,064)	3,050
Change in fair value of available-for-sale securities	(116)	0	0
Other comprehensive loss	446	(5,064)	3,050
Comprehensive loss	$ (58,938)	$ (58,708)	$ (20,868)
Net loss per share attributable to common stockholders, basic and diluted (in usd per share)	$ (2.82)	$ (4.30)	$ (1.99)
Weighted-average shares of common stock used to compute net loss per share attributable to common stockholders, basic and diluted (in shares)	21,076,246	12,482,988	12,044,447

Consolidated Statements of Rede

Consolidated Statements of Redeemable Members' Capital and Stockholders' Equity/Members' Deficit - USD ($) $ in Thousands	Total	Members Capital [Member]	Class A LLC Units [Member]	Class B LLC Units [Member]	Class C LLC Units [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Accumulated deficit [Member]	Accumulated other comprehensive income [Member]	Common Stock [Member]	Additional paid-in capital [Member]
Members' Capital, beginning balance at Dec. 31, 2012	$ 20,239	$ 0				$ 5,134	$ 9,662	$ 5,443
Increase (Decrease) in Temporary Equity [Roll Forward]
Equity restructuring	854	21,093				(5,134)	(9,662)	(5,443)
Issuance of member units			$ 44,286		$ 40,000
Issuance costs of member units	(2,194)	(2,194)
Share redemptions	(3,885)	(3,885)
Members' Capital, ending balance at Dec. 31, 2013	99,324	99,324				0	0	0
Increase (Decrease) in Temporary Equity [Roll Forward]
Temporary Equity, Limited Liability Company (LLC) Members' Equity, Unit-based Compensation	24	24
Stockholders' Equity, beginning balance at Dec. 31, 2012	(18,749)								$ (19,603)	$ 0	$ 0	$ 853
Shares, beginning balance (in shares) at Dec. 31, 2012											1,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Corporate Conversion	(854)											(853)
Corporate Conversion (in shares)											(1,000)
Net loss	(23,918)								(23,918)
Foreign currency translation adjustments	3,050									3,050
Unrealized loss on marketable securities, net	0
Stockholders' Equity, ending balance at Dec. 31, 2013	(40,471)								(43,521)	3,050	$ 0	0
Shares, ending balance (in shares) at Dec. 31, 2013											0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of member units			25,945	$ 126	$ 3
Members' Capital, ending balance at Dec. 31, 2014	125,418	125,418				0	0	0
Increase (Decrease) in Temporary Equity [Roll Forward]
Temporary Equity, Limited Liability Company (LLC) Members' Equity, Unit-based Compensation	20	20
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(53,644)								(53,644)
Foreign currency translation adjustments	(5,064)									(5,064)
Unrealized loss on marketable securities, net	0
Stockholders' Equity, ending balance at Dec. 31, 2014	(99,179)								(97,165)	(2,014)	$ 0	0
Shares, ending balance (in shares) at Dec. 31, 2014											0
Increase (Decrease) in Temporary Equity [Roll Forward]
Equity restructuring	(156,421)	(156,421)
Issuance of member units			$ 31,000	$ 3
Members' Capital, ending balance at Dec. 31, 2015	0	$ 0				$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Corporate Conversion	156,421										$ 18	156,403
Corporate Conversion (in shares)											17,581,000
Reclassification of warrant liability	1,085											1,085
Issuance of common stock	94,186										$ 7	94,179
Shares issued in IPO (in shares)											7,053,000
Net loss	(59,384)								(59,384)
Foreign currency translation adjustments	562									562
Issuance of common stock under employee stock purchase plan and vesting of restricted stock	394										$ 1	393
Issuance of common stock under employee stock purchase plan (in shares)											145,000
Exercise of stock options and warrants	96											96
Exercise of stock options and warrants (in shares)											108,000
Stock-based compensation expense	5,228											5,228
Unrealized loss on marketable securities, net	(116)									(116)
Stockholders' Equity, ending balance at Dec. 31, 2015	$ 99,293								$ (156,549)	$ (1,568)	$ 26	$ 257,384
Shares, ending balance (in shares) at Dec. 31, 2015											24,887,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (59,384,000)	$ (53,644,000)	$ (23,918,000)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	8,286,000	8,757,000	5,990,000
Loss on disposal of property and equipment	372,000	344,000	47,000
Non-cash interest expense and discount amortization	657,000	136,000	0
Amortization of premium on marketable securities, net	321,000	0	0
Change in fair value of warrant liability	435,000	0	0
Provision for doubtful accounts	979,000	466,000	992,000
Unrealized foreign currency (gain) loss	(486,000)	307,000	(358,000)
Deferred income taxes	(374,000)	890,000	(1,596,000)
Stock-based compensation	5,228,000	20,000	24,000
Loss on early retirement of debt	2,282,000	0	0
Loss on impairment of property and equipment	1,070,000	0	0
Changes in certain working capital components and other assets and liabilities:
Accounts receivable	(2,587,000)	(1,576,000)	(3,434,000)
Inventories	(4,026,000)	(2,743,000)	(9,231,000)
Prepaid expenses and other current assets	(940,000)	(1,196,000)	(2,948,000)
Other assets	394,000	287,000	(564,000)
Accounts payable, accrued expenses, and other liabilities	5,148,000	4,329,000	9,587,000
Net cash used in operations	(42,625,000)	(43,623,000)	(25,409,000)
Cash flows from investing activities:
Capital expenditures	(8,603,000)	(9,987,000)	(4,989,000)
Payments for acquisitions, net of cash acquired	0	0	(720,000)
Purchases of marketable securities	(55,352,000)	0	0
Proceeds from maturities of marketable securities	1,000,000	0	0
Net cash used in investing activities	(62,955,000)	(9,987,000)	(5,709,000)
Cash flows from financing activities:
Borrowings on line of credit	0	18,800,000	6,025,000
Payments on line of credit	0	(24,800,000)	(3,826,000)
Proceeds from term loan	43,000,000	40,000,000	0
Principal payments on term loan	(40,000,000)	0	0
Prepayment and end of term fees for early retirement of debt	(2,306,000)	0	0
Payments for debt financing fees	(417,000)	(522,000)	(78,000)
Principal payments on capital leases	0	(58,000)	(535,000)
Payments of contingent consideration	0	0	(1,010,000)
Share redemptions	0	0	(3,885,000)
Proceeds from issuance of member units, net	31,000,000	26,071,000	41,957,000
Proceeds from issuance of common stock in initial public offering, net of issuance costs	94,186,000	0	0
Proceeds from issuance of common stock under employee stock purchase plan	394,000	0	0
Proceeds from option exercises	96,000	5,000	135,000
Net cash provided by financing activities	125,953,000	59,496,000	38,783,000
Effect of exchange rate changes on cash and cash equivalents	(101,000)	(165,000)	250,000
Net increase in cash and cash equivalents	20,272,000	5,721,000	7,915,000
Cash and cash equivalents, beginning of year	13,761,000	8,040,000	125,000
Cash and cash equivalents, end of year	34,033,000	13,761,000	8,040,000
Supplemental disclosure of cash flow information:
Interest, net of capitalized interest	4,622,000	3,814,000	104,000
Income taxes	$ 40,000	$ 14,000	$ 0

Description of Business and Bac

Description of Business and Background	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Background	Description of Business and Background Description of Business EndoChoice Holdings, Inc. and its subsidiaries ("EndoChoice", or the "Company") is a medical device company headquartered in Alpharetta, Georgia focused exclusively on designing and commercializing a platform of innovative products for gastrointestinal, or GI, caregivers. The Company offers a comprehensive range of products and services that span single use devices and infection control, pathology, and imaging technologies. Since the Company began commercial operations in 2008, it has developed an extensive line of devices and infection control products and acquired pathology and scope repair services providers. The consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company has incurred losses and cash flow deficits from operations for the years ended December 31, 2015, 2014, and 2013. The Company has financed operations to date primarily through private placements of equity securities, borrowings under debt agreements, and the issuance of common stock in the initial public offering completed in June 2015. The Company’s ability to meet its obligations in the ordinary course of business is dependent upon its ability to generate sufficient cash flow to meet its obligations and ultimately to attain profitable operations. Failure to increase sales of its products, manage discretionary expenditures, or raise additional financing, if required, may adversely impact the Company’s ability to achieve its intended business objectives. Equity Restructuring On January 4, 2013, all of the issued and outstanding stock of EndoChoice, Inc. was exchanged for units of ECPM Holdings, LLC and EndoChoice, Inc. became a 100% owned subsidiary of ECPM. The exchange was accounted for using the historical cost basis of the net assets of EndoChoice, Inc. as the entities are under common control. ECPM was established on January 4, 2013 to secure $44,286 in additional capital from private equity sources to facilitate the acquisition of Peer Medical Ltd, an Israeli Company in the business of developing proprietary endoscopic systems for performing endoscopic examinations, and RMS Endoskopie Technik Stephen Wieth e.k. (RMS), a German company in the business of manufacturing, repairing, and distributing endoscopic systems. Concurrent with the exchange on January 4, 2013, additional shares in EndoChoice, Inc. were issued to existing and new shareholders and were subsequently converted to member units of ECPM. Corporate Conversion On June 4, 2015, ECPM Holdings, LLC converted into a Delaware corporation pursuant to a statutory conversion and changed its name to EndoChoice Holdings, Inc. As a result of the corporate conversion, the holders of the different classes and series of units of ECPM Holdings, LLC became holders, in aggregate, of 17,580,918 shares of common stock and 579,869 shares of restricted stock in EndoChoice Holdings, Inc. In addition, holders of options and warrants to purchase units of ECPM Holdings, LLC received an aggregate of 339,373 options and 187,161 warrants to purchase shares of EndoChoice Holdings, Inc. common stock. Initial Public Offering On June 10, 2015, the Company completed an initial public offering (the "IPO", or the "offering") of 7,302,500 shares of common stock, including 952,500 shares sold to underwriters for the exercise of their option to purchase additional shares, at an offering price of $15.00 per share. Of the 7,302,500 common shares sold in the offering, 7,052,500 shares were sold by the Company and 250,000 shares were sold by existing stockholders. The Company received net proceeds from the IPO of approximately $94,186 after deducting underwriting discounts and commissions of $7,405 and offering expenses of $4,197 . Net Loss Per Share of Common Stock Basic and diluted net loss per share of common stock reflect the conversion of all member units of ECPM Holdings, LLC to shares of EndoChoice common stock by treating all units as if they had been converted as of the beginning of the periods presented. Basic and diluted net loss per share amounts do not give effect to potentially dilutive securities where the impact would have been anti-dilutive. Reclassifications Certain prior period amounts in the accompanying consolidated financial statements have been reclassified to conform to the current period presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements are presented in accordance with United States generally accepted accounting principles. The consolidated financial statements include the accounts of EndoChoice Holdings, Inc. (formerly ECPM Holdings, LLC prior to the corporate conversion discussed above; EndoChoice Innovation Center, Ltd.; EndoChoice GmbH; and Robert S. Smith, M.D., Inc. d/b/a EndoChoice Pathology ("EC Pathology")). The Company also owns a 67% interest in EndoChoice Israel, Ltd., which had no material transactions during the years ended December 31, 2015, 2014, and 2013. All significant intercompany transactions and balances were eliminated in consolidation. Foreign Exchange Transactions The Company’s consolidated financial statements are prepared in U.S. dollars (USD). Its foreign subsidiaries use their local currency as their functional currency and maintain their records in the local currency. Accordingly, the assets and liabilities of these subsidiaries are translated into USD using the current exchange rates in effect at the balance sheet date and equity accounts are translated into USD using historical rates. Revenues and expenses are translated using the average exchange rates in effect when the transaction occurs. The resulting foreign currency translation adjustments are recorded in other comprehensive income (loss) in the consolidated balance sheets. Transactions denominated in foreign currency are remeasured at exchange rates at the date of transaction with foreign currency gains (losses) recorded in other income (expense) in the consolidated statements of comprehensive loss. The Company recognized net foreign currency transaction gains (losses) of $(1,521) , $(1,027) and $202 for the years ended December 31, 2015, 2014, and 2013, respectively. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to revenue recognition, stock-based compensation, valuation of goodwill and identifiable intangibles, tax related contingencies and valuation allowances, allowances for doubtful accounts, inventory valuation, litigation contingencies, and certain accrued liabilities. Estimates are based on assumptions that we believe are reasonable under the circumstances. Actual results may differ given the inherent uncertainty of estimates. Cash and Cash Equivalents The Company considers all short-term, highly liquid marketable securities with remaining maturities at the purchase date of three months or less to be cash equivalents. The Company invests the majority of its cash in interest-bearing accounts in U.S. banks, and the Company’s foreign subsidiaries maintain cash accounts denominated in Euros and Shekels. Foreign currency accounts are remeasured to U.S. dollars at each month-end. At times, deposit balances in the U.S. may exceed the FDIC insured limit. The Company had $16,104 of money market funds classified as cash equivalents as of December 31, 2015. The Company held no money market funds classified as cash equivalents as of December 31, 2014. Marketable Securities The Company’s short-term and long-term marketable securities consist of U.S. Treasury securities, U.S. government agency securities, commercial paper, and corporate securities. The Company’s marketable securities are classified as available-for-sale and reported at fair value, with the unrealized gains and losses, net of taxes, reported as a component of stockholders’ equity. Management determines the appropriate classification of marketable securities at the time of purchase and re-evaluates the designations at each balance sheet date. The Company classifies marketable securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable securities not classified as cash equivalents that have remaining maturities of less than one year are classified as short-term marketable securities, and marketable securities with remaining maturities one year or greater are classified as long-term marketable securities. The cost of marketable securities sold is based on the specific identification method. In addition, interest income for marketable debt securities is recorded when earned using an effective yield method, giving effect to the amortization of premiums and accretion of discounts. The Company regularly reviews its marketable securities portfolio to determine if any security is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period any such determination is made. In making this judgment, the Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company’s intent to sell, or whether it will more likely than not be required to sell, the security before recovery of its amortized cost basis. The Company’s assessment on whether a security is other-than-temporarily impaired could change in the future due to new developments or changes in assumptions related to any particular security. Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are recorded on our consolidated balance sheets at outstanding amounts, less the allowance for doubtful accounts. The allowance for doubtful accounts is set at a level that represents our best estimate of the amount of probable credit losses in our existing accounts receivable balance. The allowance is based on various factors, including an assessment of the collectability of specific customer accounts. In circumstances where a specific customer’s inability to meet its financial obligations is known or expected, we record a specific provision for bad debts to reduce the receivable to the amount that we believe will be collected. Accounts receivable are written off against the allowance for doubtful accounts when an account is deemed to be uncollectible. During the years ended December 31, 2015, 2014 and 2013, the Company recorded bad debt expense of $979 , $466 , and $992 , respectively. As of December 31, 2015 and 2014, the Company had an allowance for doubtful accounts of $940 and $860 , respectively. Inventories Inventories are valued at lower of cost or market value. Cost includes all purchase, conversion, and other direct and indirect expenditures incurred in bringing the inventory to its existing condition and location. Wages and other related benefit costs of employees directly attributable to the production process and an allocated portion of other indirect production expenses (overhead) are included in inventory costs. Overhead includes both fixed and variable expenses which are allocated to inventory produced on a systematic basis. Cost is determined using the weighted average method. The Company regularly reviews inventory quantities on hand in consideration of projected future demand, product life cycles, design changes, and remaining shelf life to record a provision for excess and obsolete inventory when appropriate. Property and Equipment Property and equipment is stated at cost, less accumulated depreciation and amortization. Repairs and maintenance are charged to expense as incurred, while significant improvements are capitalized. Depreciation is computed using the straight-line method over the following estimated useful lives of the respective assets: Years Furniture and fixtures 7 Computers and software 2–5 Demonstration equipment 2 Machinery and equipment 7 Leasehold improvements are amortized over the lesser of the estimated useful life or lease term. Upon retirement or disposal of property and equipment, the related cost and accumulated depreciation are removed from the Company’s accounts, and any resulting gain or loss is recorded in the period of retirement or disposal. Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment and intangible assets and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Factors that we consider in deciding when to perform an impairment review include significant under-performance of an asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use of the asset. If circumstances indicate potential impairment of a long-lived asset, the Company compares the undiscounted cash flows expected to be generated by the asset to the carrying amount of the asset. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. The Company determines fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. In 2015, the Company recorded impairment charges of $1,070 , primarily related to the replacement of certain demonstration equipment with newer versions of Fuse ® as indicated in Note 6. No impairment charges related to long-lived assets were recorded during 2014 and 2013. Goodwill Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets from the businesses that we acquire. The Company reviews goodwill for impairment annually, or more frequently if indicators of impairment exist. The annual impairment test is conducted as of September 30. The Company reviews goodwill for impairment by applying a quantitative impairment analysis using the two step method. Under the first step, the fair value of the reporting unit is compared with its carrying value (including goodwill). If the fair value of the reporting unit exceeds its carrying value, goodwill is not considered impaired, and we are not required to perform additional analysis. If the fair value of the reporting unit is less than its carrying value, the Company will recognize the amount of the impairment loss for any excess carrying amount of the reporting unit’s goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation, and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill. As of December 31, 2015, there has been no impairment of goodwill. Revenue Recognition The Company generates revenue primarily from the sales of GI products and pathology services. The Company sells products through direct sales representatives in the U.S. and Germany and independent distributors in international markets. Sales to distributors are recorded when title and risk of loss transfer. No direct sales customers or distributors have price protection. We recognize revenue when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) delivery obligations to the customer related to the products or services have been satisfied; (3) the arrangement consideration is fixed or determinable; and (4) the collection of the revenues is reasonably assured. GI pathology service revenue is recognized as services are performed, net of estimated reimbursement adjustments by payors. These adjustments include contractual write-downs under health insurance contracts, rebates for billing errors, and out-of-network charges. These estimates are based on the terms of contracts with health insurance payors and historical collections experience. Revenue from endoscope repair services, included in GI equipment and supplies revenue, are recognized ratably over the life of the contract. Deferred revenue is recorded for consideration received that is not yet earned due to outstanding obligations related to sales of products and services. The Company’s policy is to classify shipping and handling costs billed to customers as revenues and the related expenses as costs of revenues. Sales taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and, therefore, are excluded from revenues in the consolidated statements of comprehensive loss. The Company accrues estimated warranty reserves at the time of shipment based on contractual obligations and historical experience of related repair costs. As of December 31, 2015 and 2014, the Company had an allowance for estimated warranty claims of $922 and $207 , respectively, included in accrued expenses and other current liabilities in the accompanying consolidated balance sheets. Cost of Revenues Cost of revenues consist primarily of manufacturing overhead costs, direct material costs, and direct labor. A significant portion of our cost of revenues consists of manufacturing overhead costs, which include the cost of quality assurance, material procurement, inventory control, warehousing and shipment, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for production equipment and certain direct costs such as shipping costs. Research and Development Research and development costs, including new product development, regulatory compliance and clinical research, are charged to operations as incurred in the consolidated statements of operations and comprehensive loss. Such costs include personnel-related costs, supplies, services, depreciation, allocated facilities overhead and information services, clinical trial and related clinical manufacturing expenses, fees paid to investigative sites and other indirect costs. Research and development expense for the years ended December 31, 2015, 2014, and 2013 includes $1,345 , $3,422 , and $5,749 , respectively, of labor and overhead costs associated with certain engineering activities required to advance the design of the Fuse® product for manufacture. Stock-Based Compensation The Company accounts for stock-based compensation awards to employees and directors in accordance with the provisions of Accounting Standards Codification 718, Compensation — Stock Compensation. The Company measures stock-based compensation cost at grant date based on the estimated fair value of the award and recognizes the cost of awards expected to vest over the requisite service period. The fair value of restricted stock awards is determined based on the closing price of the Company’s stock on the grant date. The fair value of stock option awards and employee stock purchase plan grants are determined on the grant date using the Black-Scholes-Merton option-pricing model (“Black-Scholes model”). The determination of fair value on the grant date using the Black-Scholes model is affected by the Company's stock price as well as assumptions regarding a number of subjective variables. These variables include but are not limited to the expected dividend yield, expected volatility over the term of the award, risk-free interest rate, expected term, and the actual and projected employee option exercise behavior. Expected dividend yield: A zero percent dividend yield is assumed as the Company has not paid and does not expect to pay dividends on common stock. Expected volatility: Volatility is estimated for each stock option grant based on a study of publicly traded industry peer companies. In evaluating similarity, the Company considered factors such as industry, stage of development, and size. Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for zero-coupon U.S. Treasury notes with remaining terms similar to the expected term of the options. Expected term: The expected term represents the period that option awards are expected to be outstanding. Due to our limited trading history as a public company as well as limitations on the sale or transfer of stock-based compensation awards granted prior to the initial public offering discussed in Note 1, we do not believe our historical exercise pattern is indicative of the pattern that we will experience as a publicly traded company. We have consequently used the simplified method available under Staff Accounting Bulletin ("SAB) 110 to calculate the expected term, which utilizes the midpoint between the vesting date and the end of the contractual term. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such assets is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable earnings, and tax planning strategies. The income tax benefit or expense is the total current year income tax due or refundable and the change in deferred tax assets and liabilities. A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of the tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. As of December 31, 2015 and 2014, the Company has not identified any uncertain tax positions that require adjustment to or disclosure in the accompanying consolidated financial statements. The Company’s federal and state income tax returns since 2011 are subject to examination by tax authorities and may change upon examination. Comprehensive Income (Loss) Other comprehensive income (loss) refers to revenues, expenses, gains, and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings, as these amounts are recorded directly as an adjustment to stockholders’ equity. Other comprehensive income (loss) is comprised of foreign currency translation adjustments and unrealized gains (losses) on available-for-sale marketable securities. These amounts are presented in the consolidated statements of operations and comprehensive loss and redeemable members' capital and stockholders’ equity/members' deficit. Fair Value Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date under current market conditions. The Company categorizes its financial assets and liabilities into a three-level hierarchy based on the priority of the inputs to the valuation, pursuant to the Fair Value Measurements and disclosures of ASC Topic 820. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the overall fair value measurement of the instrument. Level 1 – Quoted prices available in active markets for identical investments as of the reporting date; Level 2 – Inputs other than quoted prices for identical assets or liabilities in active markets that are either directly or indirectly observable as of the reporting date; and, Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the asset or liability. These inputs reflect management judgment about the assumptions that market participants would use in valuing the asset or liability. Net Loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period. Stock options, warrants, and restricted shares are considered to be common stock equivalents and are evaluated for dilutive effect using the treasury-stock method. Basic and diluted net loss per common share are the same for years ended December 31, 2015, 2014, and 2013 due to the Company's reported net losses during those periods and the exclusion of dilutive common stock equivalents from diluted weighted-average shares of common stock outstanding.

Adoption of New Accounting Pron

Adoption of New Accounting Pronouncements	12 Months Ended
	Dec. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Adoption of New Accounting Pronouncements	Adoption of New Accounting Pronouncements In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-17, Balance Sheet Classification of Deferred Taxes, requiring all deferred tax assets and liabilities, and any related valuation allowances, to be classified as non-current on the balance sheet. The standard is effective for reporting periods beginning after December 15, 2016 and interim periods within those fiscal years, and early adoption is permitted. ASU 2015-17 may be applied either prospectively to all deferred tax assets and liabilities or retrospectively to all periods presented. The guidance was early adopted in the fourth quarter of 2015, as permitted, on a prospective basis. The adoption affected only the presentation of deferred taxes on the consolidated balance sheets and had no impact on the Company's results of operations. In April 2015, the FASB issued ASU 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 will require an entity to present debt issuance costs in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than as an asset, consistent with the treatment of debt discounts. The amendment does not change the recognition and measurement guidance for debt issuance costs, and the amortization of debt issuance costs will continue to be reported as interest expense. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2016. The Company early adopted ASU 2015-03 in June 2015, as permitted, and applied the new guidance retrospectively to the consolidated balance sheet as of December 31, 2014. There was no impact from the early adoption of ASU 2015-03 on the Company's results of operations. December 31, 2014 Prior to Adoption of ASU 2015-03 Effect of Adoption As Adopted Prepaid expenses and other current assets $ 2,774 $ (411 ) $ 2,363 Total current assets 39,521 (411 ) 39,110 Total assets 87,220 (411 ) 86,809 Long-term debt $ 39,350 $ (411 ) $ 38,939 Total liabilities 60,981 (411 ) 60,570 Future Adoption of Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is in the process of evaluating the impact of this new guidance. In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016-01 is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company is currently evaluating the impact of the future adoption of this standard, but the adoption is not expected to have a material effect on the consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. ASU 2015-11 changes the measurement principle for inventory for entities using FIFO or average cost from the lower of cost or market to lower of cost and net realizable value. ASU 2015-11 defines net realizable value as estimated selling prices in the ordinary course of business less reasonably predictable costs of completion, disposal, and transportation. The standard is effective for reporting periods beginning after December 15, 2016 and interim periods within those fiscal years with early adoption permitted. ASU 2015-11 should be applied prospectively. The Company is currently evaluating the impact of the future adoption of this standard, but the adoption is not expected to have a material effect on the consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern at each annual and interim period. Related footnote disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year after the report issuance date. If conditions do not give rise to substantial doubt, no disclosures will be required specific to going concern uncertainties. The ASU defines substantial doubt using a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies and provides example indicators. ASU 2014-15 is effective for reporting periods ending after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the future adoption of this standard, but the adoption is not expected to have a material effect on the consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosures about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09, as specified in ASU 2015-14, is now effective for reporting periods beginning after December 15, 2017. Earlier adoption is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. We are currently evaluating the impact of the future adoption of this standard.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements As of December 31, 2015, the Company holds a portfolio of available-for-sale marketable securities recorded at fair value on the consolidated balance sheets (as discussed in Note 4). The Company had no marketable securities as of December 31, 2014. Other financial assets and liabilities recorded in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 that require fair value disclosure include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, and long-term debt. The estimated fair values of these financial assets and liabilities as of December 31, 2015 and 2014 reasonably approximate their respective carrying values as reported within the consolidated balance sheets. As of December 31, 2015 and 2014, contingent liabilities for accrued earn-out consideration were categorized as Level 3 within the fair value hierarchy and were recorded at fair value on the acquisition date and are remeasured periodically based on the then assessed fair value. These liabilities are adjusted if deemed necessary and have been recorded in other long-term liabilities within the consolidated balance sheets. The increases or decreases in the fair value of these contingent consideration liabilities can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measures are based on significant inputs that are not observable in the market, they are categorized as Level 3. As of December 31, 2014, warrants issued to Triple Point Capital, LLC in connection with the Growth Capital Facility (as defined in Note 10) were categorized as Level 3 within the fair value level hierarchy. As a result of the corporate conversion on June 4, 2015 (see Note 1), the warrants were converted from warrants to purchase 2,091,175 Class A member units in ECPM Holdings, LLC at an exercise price of $0.96 to warrants to purchase 183,100 shares of EndoChoice Holdings, Inc. common stock at an exercise price of $10.95 . Accordingly, the warrant liability was remeasured to fair value on the date of the corporate conversion and reclassified from other long-term liabilities to additional paid-in capital on the condensed consolidated balance sheet. The Company recognized losses of $435 within other expense on the consolidated statement of operations and comprehensive loss during the year ended December 31, 2015, respectively, due to increases in the fair value of the warrant liability during those periods through the date of the corporate conversion. The fair value of the warrant liability was determined using the Black-Scholes-Merton option pricing model, which resulted in an estimate of fair value at the time of conversion that was consistent with the value of the common shares issued to the warrant holders upon the full exercise of the warrants on June 16, 2015. For the Company’s assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the following table provides a reconciliation of the beginning and ending balances for each category therein and gains or losses recognized during the period: Fair value measurements using significant unobservable inputs (level 3): Contingent liabilities for accrued earn-out acquisition consideration Warrants Balance as of January 1, 2014 $ 673 $ — Foreign currency translation adjustments (41 ) — Issuance of warrants — 650 Balance as of December 31, 2014 632 650 Foreign currency translation adjustments (31 ) — Remeasurement to fair value (208 ) 435 Reclassification from other long-term liabilities to additional paid-in-capital — (1,085 ) Balance as of December 31, 2015 $ 393 $ — Within the consolidated balance sheets, the current portion of contingent liabilities for accrued earn-out acquisition consideration are included in accrued expenses and other current liabilities, while the non-current portion is included in other long-term liabilities. The determination of current versus non-current is made based on the expected timing of the payments from the balance sheet date. Amounts expected to be paid within twelve months of the balance sheet date are classified as current, and amounts expected to be paid after twelve months from the balance sheet date are classified as non-current. As of December 31, 2015, $110 and $283 of contingent liabilities for accrued-earnout acquisition consideration were included in accrued expenses and other current liabilities and other long-term liabilities, respectively. As of December 31, 2014, all contingent liabilities for accrued-earnout acquisition consideration were classified as non-current and included within other long-term liabilities.

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities The table below summarizes the Company’s available-for-sale marketable securities' amortized cost, gross unrealized gains, gross unrealized losses, and fair value by significant investment category recorded as short-term marketable securities or long-term marketable securities as of December 31, 2015 (refer to Note 2 for discussion of our fair value hierarchy). The Company had no marketable securities as of December 31, 2014. Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term Marketable Securities Long-term Marketable Securities Level 1: U.S. Treasuries $ 4,017 $ — $ (10 ) $ 4,007 $ 2,004 $ 2,003 U.S. government agencies 3,656 — (9 ) 3,647 1,556 2,091 Subtotal 7,673 — (19 ) 7,654 3,560 4,094 Level 2: Commercial paper 3,998 — — 3,998 3,998 — Corporate securities 42,065 1 (98 ) 41,968 26,314 15,654 Subtotal 46,063 1 (98 ) 45,966 30,312 15,654 Total $ 53,736 $ 1 $ (117 ) $ 53,620 $ 33,872 $ 19,748 The amortized cost and fair value of short-term and long-term marketable securities as of December 31, 2015 are shown below by contractual maturity. Actual maturities may differ from contractual maturities as securities may be restructured, called, or prepaid. Amortized Cost Fair Value Due to mature: Less than one year $ 33,929 $ 33,872 One to two years 19,807 19,748 Total $ 53,736 $ 53,620 No realized gains and losses were recognized on the sale of marketable securities for any of the periods presented. As of December 31, 2015, net unrealized losses of $116 , net of tax, were included in accumulated other comprehensive loss in the accompanying consolidated balance sheets. There were no transfers between Level 1 and Level 2 fair value measurements during the year ended December 31, 2015, and there were no changes in the valuation techniques used by the Company.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following: December 31, 2015 2014 Raw materials $ 6,821 $ 4,428 Work-in-process 3,113 3,282 Finished goods 7,539 5,927 Total inventories $ 17,473 $ 13,637

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consisted of the following: December 31, 2015 2014 Furniture and fixtures $ 1,229 $ 925 Leasehold improvements 2,244 2,053 Computers and software 3,245 2,864 Demonstration equipment 8,414 6,553 Machinery and equipment 6,428 3,666 Construction in progress 1,015 — Total 22,575 16,061 Accumulated depreciation (11,052 ) (6,393 ) Property and equipment, net $ 11,523 $ 9,668 Depreciation expense was $5,533 , $4,849 , and $1,412 for the years ended December 31, 2015, 2014, and 2013, respectively. During the year ended December 31, 2015, we recognized an impairment of $1,029 on demonstration equipment due to the replacement of certain of this equipment with newer versions of Fuse ®. The loss is recorded in sales and marketing expense in the consolidated statements of operations and comprehensive loss. No impairment on demonstration equipment was recognized during the years ended December 31, 2014 and 2013.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for amortizable intangible assets as of December 31, 2015 and December 31, 2014 are as follows: December 31, 2015 December 31, 2014 Gross carrying amount Accumulated amortization Net carrying value Gross carrying amount Accumulated amortization Net carrying value Amortizable intangible assets: Customer relationships $ 1,683 $ (732 ) $ 951 $ 1,845 $ (595 ) $ 1,250 Developed technology 20,498 (7,687 ) 12,811 20,435 (5,109 ) 15,326 Other intangible assets 2,198 (2,141 ) 57 2,203 (2,124 ) 79 Total amortizable intangible assets $ 24,379 $ (10,560 ) $ 13,819 $ 24,483 $ (7,828 ) $ 16,655 Unamortizable intangible assets: Goodwill $ 20,105 $ — $ 20,105 $ 20,301 $ — $ 20,301 The Company recorded amortization expense related to the amortizable intangible assets of $2,753 , $3,908 , $4,578 for the years ended December 31, 2015, 2014, and 2013, respectively. As of December 31, 2015, estimated aggregate future amortization expense for the intangible assets is as follows: Estimated amortization expenses: 2016 $ 2,735 2017 2,735 2018 2,735 2019 2,735 2020 2,721 Thereafter 158 Total $ 13,819 Changes in the carrying amount of amortizable intangible assets and goodwill for the years ended December 31, 2015 and 2014 are as follows: Amortizable intangible assets: Balance at December 31, 2014 $ 16,655 Amortization (2,753 ) Foreign currency translation adjustment (83 ) Balance at December 31, 2015 $ 13,819 Goodwill: Balance at December 31, 2014 20,301 Foreign currency translation adjustment (196 ) Balance at December 31, 2015 $ 20,105

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: December 31, 2015 2014 Payroll and employee related expenses $ 4,787 $ 4,293 Accrued warranty costs 922 207 Sales and other taxes payable 320 438 Other accrued liabilities 3,174 3,390 Accrued expenses and other current liabilities $ 9,203 $ 8,328

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt	Debt The Company had $42,643 and $38,939 in total debt outstanding, net of discount, as of December 31, 2015 and December 31, 2014, respectively, which is fully included in long-term debt on our consolidated balance sheets. Effective June 30, 2015, the Company refinanced its outstanding debt by entering into a new term loan credit and security agreement (the "Term Loan Credit Agreement") and a new revolving loan credit and security agreement (the "Revolving Loan Credit Agreement", and together with the Term Loan Credit Agreement, the "Credit Agreements") each dated June 30, 2015 (the "Closing Date") by and among EndoChoice and certain of its subsidiaries, MidCap Financial Trust, and Silicon Valley Bank. The Credit Agreements contain representations and covenants typical for credit arrangements of comparable size in the medical device industry, including certain financial covenants related to minimum liquidity levels and net revenues. The Credit Agreements also contain customary events of default. If an event of default occurs and is not cured within any applicable grace period or is not waived, the creditors are entitled to take various actions, including, without limitation, the acceleration of amounts due thereunder, termination of commitments under the Credit Agreements, and realization upon the collateral securing the credit facilities. Term Loan Facility The Term Loan Credit Agreement provides for a five -year $43,000 senior term loan facility (the "Term Loan Facility") secured by a lien on substantially all of the assets of EndoChoice and its domestic subsidiaries, other than intellectual property, which is subject to a negative pledge only. The Term Loan Facility bears interest at a fixed rate of 9.5% per year and is subject to an end of term fee of 2.95% on the $43,000 advanced under the facility on the Closing Date. Interest-only payments are due during the first 30 months of the Term Loan Facility, with principal payments beginning in January 2018 in equal monthly installments until maturity. The end of term fee is not applied to scheduled principal payments and is due only upon the earlier of repayment or maturity of the loan. The end of term fee is accrued as additional interest expense using the effective interest rate method over the term of the loan. We incurred debt issuance costs of $417 in connection with entering into the Term Loan Facility. Pursuant to our adoption of ASU 2015-03 as discussed in Note 2, we recognized the debt issuance costs, including deferred financing costs, as a direct deduction from the carrying amount of the long-term debt outstanding under the Term Loan Facility. The debt issuance costs will be amortized each period after the Closing Date using the effective interest method and will be reported as interest expense. Proceeds from the Term Loan Facility were used to voluntarily prepay $40,000 of outstanding loans under the Growth Capital Loan and Security Agreement dated February 18, 2014 with Triple Point Capital, LLC (the "Growth Capital Facility"), to pay $2,306 of prepayment and end of term fees, and to pay $517 of other fees and expenses in connection with the refinancing. Revolving Credit Facility The Revolving Loan Credit Agreement provides for a five -year $15,000 senior revolving credit facility (the "Revolving Credit Facility") also secured by a lien on substantially all of the assets of EndoChoice and its domestic subsidiaries, other than intellectual property, which is subject to a negative pledge only. Amounts drawn under the Revolving Credit Facility will bear interest at the LIBOR Rate (as defined in the Revolving Loan Credit Agreement) plus 5.25% per year, while the undrawn portion is subject to an unused line fee of 0.50% per year. No amounts were drawn or outstanding under the Revolving Credit Facility as of December 31, 2015. The Revolving Credit Facility expires on June 30, 2020. Early Debt Retirement Concurrently with entering into the Credit Agreements described above, on June 30, 2015, the Company repaid all outstanding loans under and terminated the Growth Capital Facility with Triple Point Capital, LLC. In connection with such termination, the Company recognized a loss on early retirement of debt of $ 2,282 in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2015. In accordance with Accounting Standards Codification (“ASC”) 470 - Debt, the loss on early retirement of debt was calculated based on the difference between the amount paid to retire the debt less its net carrying value on the repayment date, adjusted for the write-off of certain unamortized balances such as deferred financing costs and debt discounts. No loss on early retirement of debt was recognized during the years ended December 31, 2014 and 2013. Also concurrently with entering into the Credit Agreements described above, on June 30, 2015, the Company terminated the Loan and Security Agreement dated as of September 9, 2013 for its line of credit with Silicon Valley Bank. There were no outstanding amounts owed under the line of credit with Silicon Valley Bank at the time of termination. Debt Repayment Schedule As of December 31, 2015, the outstanding debt repayment schedule is as follows: 2018 $ 17,200 2019 17,200 2020 8,600 Principal amounts repayable 43,000 Unamortized debt discount (357 ) Total long-term debt, net of discount $ 42,643 In addition to principal amounts repayable, end of term fees of $1,269 are due at maturity of the Term Loan Facility. A liability for end of term fees is accreted each period using our effective borrowing rate with a corresponding charge to interest expense. As of December 31, 2015, the Company has accrued $118 for end of term fees within other long-term liabilities on the consolidated balance sheets.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases The Company has certain minimum obligations under noncancelable operating lease agreements, principally in connection with office and warehouse space, which contain provisions for rent-free periods. The total amount of rental payments due over the lease terms are being charged to rent expense using the straight-line method over the terms of the leases. In October 2015, the Company entered into a noncancelable operating lease for additional office space in Alpharetta, Georgia and extended the terms of its other leases in Alpharetta, Georgia to conform all of the leases to a common end date in the second quarter of 2022. Rent expense associated with noncancelable operating leases totaled $1,359 , $1,188 , and $848 for the years ended December 31, 2015, 2014, and 2013, respectively. Future minimum lease payments under noncancelable operating leases at December 31, 2015 are as follows: Amount Year: 2016 $ 1,610 2017 1,714 2018 1,494 2019 1,466 2020 956 Thereafter 1,183 Total $ 8,423 Legal Matters The Company is party to various lawsuits and claims arising in the ordinary course of business. While the results of lawsuits or other proceedings against the Company cannot be predicted with certainty, in the opinion of management, such matters are adequately reserved for, or if not so reserved are without merit, or are of a nature that if disposed of unfavorably, involve amounts that would not have a material adverse effect on the consolidated financial position, results of operations, or liquidity of the Company.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Incentive Plans Our equity incentive plans are broad-based, long-term programs intended to attract, motivate, and retain talented non-employee directors, officers, and employees and to align their interests with stockholders. For the year ended December 31, 2015, the Company made new grants under the following equity incentive plans: 2015 Omnibus Equity Incentive Plan In June 2015, the Company adopted the 2015 Omnibus Equity Incentive Plan (the "2015 Plan"). The 2015 plan allows for the granting of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance unit awards, performance share awards, cash-based awards, and other stock-based awards to eligible individuals. It is the Company's policy that before stock is issued through the exercise of stock options, the Company must first receive all required cash payment for such shares. Upon the exercise of options, the Company issues new common stock from its authorized shares. A total of 1,260,664 shares of our common stock were reserved for issuance under the 2015 Plan. As of December 31, 2015, 578,713 stock options and 649,067 shares of restricted stock have been granted under the 2015 Plan. The 2015 Plan contains an “evergreen” provision allowing for an annual increase in the number of shares of our common stock available for issuance under the 2015 Plan on January 1 of each year during the period beginning January 1, 2016 and ending on (and including) January 1, 2025. The annual increase in the number of shares will be equal to four percent ( 4% ) of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; provided, however, that our board of directors is authorized to act prior to the first day of any calendar year to determine if the increase will be a lesser number of shares of common stock than would otherwise occur. Employee Stock Purchase Plan In June 2015, the Company adopted an Employee Stock Purchase Plan (the "ESPP"). The ESPP is designed to allow our eligible employees to purchase shares of our common stock with accumulated payroll deductions of up to 15% of eligible compensation, subject to a purchase limitation of the lesser of 5,000 shares per offering period or $25 in fair market value of shares of common stock (determined at the time the option to purchase shares under the ESPP is granted) per annual period. The first offering period under the ESPP began on July 1, 2015 and concluded on December 31, 2015. During the year ended December 31, 2015, 55,076 shares of common stock were issued under the ESPP, and $165 of stock-based compensation expense was recognized related to the ESPP. 2013 Incentive Unit Plan In January 2013, the Company adopted the 2013 Incentive Unit Plan (the "2013 Plan"). The 2013 plan allowed for the granting of incentive unit awards to employees, non-employee directors, and consultants. Incentive units were converted to 274,808 shares of common stock and 579,869 shares of restricted stock upon the Company's corporate conversion discussed in Note 1. Of the 579,869 shares of restricted stock, 149,086 were related to incentive unit awards granted during 2015. No new awards may be made under the 2013 Plan subsequent to the Company's corporate conversion on June 4, 2015; however, 497,323 shares of restricted stock granted under the plan are outstanding as of December 31, 2015 and continue to vest pursuant to the terms of their original award agreements. 2010 Peer Medical Ltd. Israeli Share Option Plan In 2012, one of our predecessors adopted the Peer Medical Ltd. 2010 Israeli Share Option Plan, or 2010 Share Option Plan. In 2013, in connection with our acquisition of Peer Medical, we assumed the 2010 Share Option Plan. No new awards may be made under the 2010 Share Option Plan subsequent to January 4, 2013; however, stock options granted under the plan prior to this date continue to vest or remain outstanding until their original expiration date. 2007 Stock Incentive Plan In December 2007, one of our predecessors adopted the EndoChoice, Inc. 2007 Stock Incentive Plan (the "2007 Plan"). The 2007 Plan, as amended and restated, was assumed by the Company in January 2013. No new awards may be made under the 2007 Plan subsequent to January 4, 2013; however, stock options granted under the plan prior to this date continue to vest or remain outstanding until their original expiration date. Stock Options Following is a summary of stock option activity for the year ended December 31, 2015: Number of Options Weighted average exercise price Weighted average remaining contractual term Aggregate Intrinsic Value Outstanding at December 31, 2014 341,345 $ 2.30 5.2 years Granted 578,713 15.89 Exercised (41,455 ) 8.11 Forfeited (30,203 ) 15.54 Outstanding at December 31, 2015 848,400 11.10 7.7 years $ 1,804 Vested and expected to vest at December 31, 2015 781,400 10.70 7.5 years 1,804 Vested and exercisable at December 31, 2015 304,745 $ 2.58 4.2 years $ 1,804 We estimate the fair value of stock options at the grant date using the Black-Scholes-Merton option pricing model. The weighted-average grant-date fair value of stock options granted for the year ended December 31, 2015 was $6.38 . No stock options were granted during the years ended December 31, 2014 and 2013. As of December 31, 2015, there was $2,953 of total unrecognized compensation cost related to stock options. These costs are expected to be recognized over a weighted average period of 3.6 years . The aggregate pre-tax intrinsic value of stock options exercised during the years ended December 31, 2015, 2014, and 2013 was $456 , $326 , and $38 , respectively. Cash received for options exercised during the years ended December 31, 2015, 2014, and 2013 was $96 , $5 , and $135 , respectively. Restricted Stock Following is a summary of the restricted stock activity for the year ended December 31, 2015: Number of Restricted Stock Shares Weighted-Average Grant-Date Fair Value Unvested at December 31, 2014 715,577 $ 3.28 Granted 798,153 15.92 Vested (366,722 ) 4.33 Forfeited (63,215 ) 11.14 Unvested at December 31, 2015 1,083,793 $ 12.39 For years ended December 31, 2015, 2014 and 2013, the weighted average grant date fair value of shares granted was $15.92 , $5.53 , and $2.69 , respectively. For the years ended December 31, 2015, the total fair value of restricted stock vested was $5,339 . No shares of restricted stock vested in 2014 and 2013. As of December 31, 2015, total unrecognized compensation cost related to restricted stock shares was $9,464 , net of estimated forfeitures, which is expected to be recognized over a weighted-average period of 3.1 years . Estimated Grant Date Fair Values The Company estimated the grant-date fair values of restricted stock grants made after the initial public offering on June 5, 2015 based on the adjusted closing price of EndoChoice Holdings, Inc. common shares on the respective grant dates. For grants made prior to our initial public offering, the Company estimated the underlying grant-date fair values of the restricted stock shares using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the “AICPA Practice Guide") . For grants made during the second quarter of 2015, including for determining changes in grant-date fair values associated with the modification that occurred on May 7, 2015 discussed further below, the Company completed a valuation of its equity utilizing the probability-weighted expected return method (“PWERM”) as outlined in the AICPA Practice Aid. The company utilized the PWERM because it could reasonably estimate the form and timing of a potential liquidity event, as preparations for the Company’s IPO had commenced. Under the PWERM valuation method, the per share value of equity is estimated based upon the probability-weighted present value of expected future equity values under various possible future liquidity event scenarios. For grants made prior to second quarter of 2015, the Company utilized the option pricing method (“OPM"), an accepted valuation method under the AICPA Practice Guide. The OPM values each equity class by creating a series of call options on the equity value, with exercise prices based on the liquidation preferences, participation rights, and strike prices of derivatives. Prior to starting preparations for the Company’s IPO, the OPM was utilized because the Company could not reasonably estimate the form and timing of potential liquidity events. Modification All holders of shares of restricted stock of EndoChoice as of June 30, 2015 originally held incentive units of ECPM Holdings, LLC prior to the corporate conversion discussed in Note 1. On May 7, 2015, the terms of the incentive unit awards were modified to provide for the exchange of unvested incentive units for unvested shares of restricted stock upon consummation of the corporate conversion. Under the original terms of the incentive award agreements, unvested incentive units were to be canceled and forfeited upon a liquidity event. In accordance with the provisions of Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation, the aforementioned change of terms resulted in a modification of the vesting terms for unvested incentive units and re-measurement of fair value for purposes of determining stock-based compensation expense. As a result of the modification, total unrecognized compensation cost for incentive unit grants to 55 employees and non-employee directors increased from $2,353 to $5,160 , net of estimated forfeitures. Stock-based Compensation Expense Stock-based compensation expense is recorded within the operating expense captions in the consolidated statements of operations and comprehensive loss based on the employees receiving the awards. We recognized stock-based compensation expense as follows for the years ended December 31, 2015, 2014, and 2013: Years Ended December 31, 2015 2014 2013 Cost of revenues $ 143 $ — $ — Research and development 623 4 5 Sales and marketing 688 4 5 General and administrative 3,774 12 14 Total $ 5,228 $ 20 $ 24 Stock-based compensation expense during the year ended December 31, 2015 includes $3,496 of previously unrecognized compensation cost that was incurred in June 2015 for restricted stock grants that vested in connection with our initial public offering, or IPO, discussed in Note 1. The restricted stock grants made prior to the IPO contained vesting criteria based on both service ( four years) and performance (the achievement of a minimum valuation threshold upon a liquidity event or initial public offering). The minimum valuation threshold was achieved in connection with our IPO. The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company’s stock-based compensation plans and rights to acquire stock granted under the Company’s ESPP. The weighted average estimated fair values of stock options, the rights to acquire stock granted, and the weighted average assumptions used in calculating those fair values were as follows: Years Ended December 31, 2015 2014 2013 Stock Options Risk free interest rate 1.6 % — % — % Expected term (in years) 5.0 0 0 Expected volatility 45.0 % — % — % Dividend yield — % — % — % Weighted average fair value at grant date $ 6.38 $ — $ — Employee Stock Purchase Plan Risk free interest rate 0.1 % — % — % Expected term (in years) 0.5 0 0 Expected volatility 47.0 % — % — % Dividend yield — % — % — % Weighted average fair value at grant date $ 4.65 $ — $ —

Net Loss per Common Share

Net Loss per Common Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Common Share	Net Loss per Common Share After giving effect to the corporate conversion as described in Note 1, the following table provides a reconciliation of the numerator and denominator used in calculating basic and diluted net loss per share attributable to common stockholders for the years ended December 31, 2015, 2014, and 2013, respectively. Years Ended December 31, 2015 2014 2013 Numerator: Net loss attributable to common stockholders $ (59,384 ) $ (53,644 ) $ (23,918 ) Denominator: Weighted-average common shares outstanding - basic 21,076,246 12,482,988 12,044,447 Dilutive effect of stock options, warrants, and restricted stock units¹ — — — Weighted-average common shares outstanding - diluted 21,076,246 12,482,988 12,044,447 Net loss per share attributable to common stockholders - basic and diluted $ (2.82 ) $ (4.30 ) $ (1.99 ) ¹Potentially dilutive stock options, warrants, and restricted stock were excluded from the calculation of diluted weighted-average shares outstanding as they would have had an anti-dilutive effect due to losses reported during the years ended December 31, 2015, 2014, and 2013. The treasury stock method is used to determine the dilutive effect of the Company’s potentially dilutive securities. The following securities were excluded from the calculation of diluted shares outstanding due to their anti-dilutive effect: December 31, 2015 2014 2013 Stock options 848,400 341,345 391,526 Warrants for common stock 4,061 187,161 4,061 Restricted stock 1,083,793 — — Total 1,936,254 528,506 395,587

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the years ended December 31, 2015, 2014, and 2013, net loss before income taxes consists of the following: 2015 2014 2013 U.S. operations $ (57,726 ) $ (57,444 ) $ (14,458 ) Foreign operations (2,019 ) 4,716 (11,018 ) $ (59,745 ) $ (52,728 ) $ (25,476 ) Income tax benefit (expense) attributable to net loss consists of the following for the years ended December 31, 2015, 2014, and 2013: Current Deferred Total Year ended December 31, 2015: U.S. federal $ — $ — $ — State and local (13 ) — (13 ) Foreign jurisdiction — 374 374 $ (13 ) $ 374 $ 361 Year ended December 31, 2014: U.S. federal $ — $ — $ — State and local (8 ) — (8 ) Foreign jurisdiction (18 ) (890 ) (908 ) $ (26 ) $ (890 ) $ (916 ) Year ended December 31, 2013: U.S. federal $ — $ — $ — State and local (38 ) — (38 ) Foreign jurisdictions — 1,596 1,596 $ (38 ) $ 1,596 $ 1,558 The effective tax rates for the years ended December 31, 2015, 2014 and 2013 are lower than the federal statutory rate primarily due to the favorable foreign tax rate differential and valuation allowances. A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective income tax rate for the years ended December 31, 2015, 2014 and 2013 is as follows: 2015 2014 2013 Tax at statutory rate 34.00 % 34.00 % 34.00 % State taxes 10.64 % 2.64 % 1.55 % Other/permanent items (2.63 )% (0.28 )% (2.58 )% Foreign rate differential (0.22 )% 0.60 % (2.81 )% Change in valuation allowance (41.19 )% (38.68 )% (23.96 )% Effective tax rate 0.60 % (1.72 )% 6.20 % Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table summarizes the significant components of our deferred tax assets and liabilities as of December 31, 2015 and 2014: 2015 2014 Deferred tax assets: Accounts receivable, principally due to allowance for doubtful accounts $ 334 $ 310 Inventories 521 370 Compensated absences, principally due to accrual for financial reporting purposes 244 300 Compensated bonuses, principally due to accrual for financial reporting purposes 465 411 Net operating loss carryforwards 52,065 30,465 Property and equipment, principally due to differences in depreciation 1,519 875 Other 1,311 658 Total gross deferred tax assets 56,459 33,389 Less valuation allowance (55,842 ) (32,212 ) Net deferred tax assets 617 1,177 Deferred tax liabilities: Intangibles (3,110 ) (4,038 ) Other — (316 ) Total gross deferred liabilities (3,110 ) (4,354 ) Net deferred tax liability $ (2,493 ) $ (3,177 ) As discussed in Note 2, the Company elected to early adopt Accounting Standards Update ("ASU") 2015-17 on a prospective basis, which resulted in all deferred taxes being netted on a jurisdictional basis and reported as non-current on the consolidated balance sheet as of December 31, 2015. As permitted when applying ASU 2015-17 on a prospective basis, the presentation of deferred taxes on the consolidated balance sheet as of December 31, 2014 was not changed. The net deferred tax liability as of December 31, 2014 includes $970 of current deferred tax assets, $207 of non-current deferred tax assets and $4,354 of non-current deferred tax liabilities. The non-current deferred taxes have been netted together in the consolidated balance sheet as of December 31, 2014. The valuation allowance for deferred tax assets as of December 31, 2015 and 2014 was ($55,842) and ($32,212) , respectively. The valuation allowances at December 31, 2015 and 2014 were primarily related to federal, state, and foreign net operating loss carryforwards that, in the judgment of management, are not more likely than not to be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income, and tax planning strategies in making this assessment. No liability for uncertain tax positions has been recorded as of December 31, 2015 or December 31, 2014. As of December 31, 2015, the Company has operating loss carryforwards for federal income tax purposes of $124,822 , which are available to offset future federal taxable income, if any, through 2035. The Company has operating loss carryforwards for state income tax purposes of $128,730 , which are available to offset future state taxable income through 2035. The Company has operating loss carryforwards from its international jurisdictions of $5,422 , which are available to offset future taxable income indefinitely. Future sales of equity and other transactions could limit the amount of net operating loss carryforwards that could be utilized annually in the future to offset taxable income, if any.

Segment, Geographical, and Cust

Segment, Geographical, and Customer Concentration	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment, Geographical, and Customer Concentration	Segment, Geographical, and Customer Concentration The Company is globally managed as one reportable segment, which is consistent with how management reviews the business, makes investing and resource allocation decisions, and assesses operating performance. The Company’s geographic regions consist of the United States and other areas, which are referred to as international. The following table represents net revenues by geographic area based on the location of the customer during the years ended December 31, 2015, 2014, and 2013: Years Ended 2015 2014 2013 United States $ 64,675 $ 54,570 $ 45,457 International 7,625 6,849 5,434 Total $ 72,300 $ 61,419 $ 50,891 For the years ended December 31, 2015, 2014, and 2013, no customers accounted for greater than 10% of revenues. Additionally, no customers accounted for greater than 10% of accounts receivable as of December 31, 2015 or 2014. The composition of the Company’s long-lived assets, consisting of property and equipment, amortizable intangible assets, and goodwill by geographic area is set forth below: December 31, 2015 2014 United States $ 7,694 $ 6,516 Israel 31,694 33,855 Other Regions 6,059 6,253 Total $ 45,447 $ 46,624

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Retirement Plans	Retirement Plans EndoChoice, Inc. has a 401(k) plan covering all of its U.S. employees after one month of employment. The 401(k) plan provides for discretionary matching contributions, and a discretionary profit sharing contribution by the Company, as determined by the board of directors. The Company made no matching or profit sharing contributions to the 401(k) plan during 2015, 2014, or 2013. EndoChoice Innovation Center, Ltd. contributes to severance pay funds and insurance policies on behalf of its employees, as required by Israeli law. The Company made a total of approximately $987 , $802 , and $360 of such contributions during 2015, 2014, and 2013, respectively. EndoChoice GmbH maintains pension plans in accordance with German law and an additional retirement plan for certain employees (together, "German Retirement Plans"). The Company contributed approximately $0 , $5 , and $3 to the German Retirement Plans during 2015, 2014, and 2013, respectively. EndoChoice GmbH also maintains a discretionary savings plan for its employees and contributed approximately $20 , $2 , and $5 to this plan during 2015, 2014, and 2013, respectively.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (Unaudited)	Selected Quarterly Financial Data (Unaudited) Quarter Ended March 31 June 30 September 30 December 31 (In thousands, except per share data) Year Ended December 31, 2015 Net revenues $ 16,748 $ 18,642 $ 18,363 $ 18,547 Gross profit 5,579 6,533 6,141 5,057 Operating loss (12,451 ) (14,824 ) (10,443 ) (12,538 ) Net loss (15,274 ) (19,487 ) (11,578 ) (13,045 ) Net loss per share attributable to common stockholders, basic and diluted¹ $ (1.00 ) $ (1.01 ) $ (0.47 ) $ (0.53 ) Year Ended December 31, 2014 Net revenues $ 13,847 $ 15,081 $ 14,169 $ 18,322 Gross profit 6,394 5,291 5,791 5,035 Operating loss (10,138 ) (12,566 ) (11,710 ) (12,801 ) Net loss (10,878 ) (13,708 ) (14,027 ) (15,031 ) Net loss per share attributable to common stockholders, basic and diluted¹ $ (0.90 ) $ (1.13 ) $ (1.16 ) $ (1.10 ) ¹Net loss per share is calculated independently for each quarter presented. Therefore, the sum of the quarterly net loss per share amounts will not necessarily equal the total for the year.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS (in thousands) Balance at beginning of period Additions Deductions Balance at end of period Year ended December 31, 2013 Allowance for doubtful accounts 315 992 (267 ) 1,040 Deferred income tax valuation allowance 5,653 6,351 — 12,004 Year ended December 31, 2014 Allowance for doubtful accounts 1,040 466 (646 ) 860 Deferred income tax valuation allowance 12,004 20,208 — 32,212 Year ended December 31, 2015 Allowance for doubtful accounts 860 979 (899 ) 940 Deferred income tax valuation allowance 32,212 23,630 — 55,842

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Foreign Exchange Transactions	Foreign Exchange Transactions The Company’s consolidated financial statements are prepared in U.S. dollars (USD). Its foreign subsidiaries use their local currency as their functional currency and maintain their records in the local currency. Accordingly, the assets and liabilities of these subsidiaries are translated into USD using the current exchange rates in effect at the balance sheet date and equity accounts are translated into USD using historical rates. Revenues and expenses are translated using the average exchange rates in effect when the transaction occurs. The resulting foreign currency translation adjustments are recorded in other comprehensive income (loss) in the consolidated balance sheets. Transactions denominated in foreign currency are remeasured at exchange rates at the date of transaction with foreign currency gains (losses) recorded in other income (expense) in the consolidated statements of comprehensive loss.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to revenue recognition, stock-based compensation, valuation of goodwill and identifiable intangibles, tax related contingencies and valuation allowances, allowances for doubtful accounts, inventory valuation, litigation contingencies, and certain accrued liabilities. Estimates are based on assumptions that we believe are reasonable under the circumstances. Actual results may differ given the inherent uncertainty of estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term, highly liquid marketable securities with remaining maturities at the purchase date of three months or less to be cash equivalents. The Company invests the majority of its cash in interest-bearing accounts in U.S. banks, and the Company’s foreign subsidiaries maintain cash accounts denominated in Euros and Shekels. Foreign currency accounts are remeasured to U.S. dollars at each month-end. At times, deposit balances in the U.S. may exceed the FDIC insured limit.
Marketable Securities	Marketable Securities The Company’s short-term and long-term marketable securities consist of U.S. Treasury securities, U.S. government agency securities, commercial paper, and corporate securities. The Company’s marketable securities are classified as available-for-sale and reported at fair value, with the unrealized gains and losses, net of taxes, reported as a component of stockholders’ equity. Management determines the appropriate classification of marketable securities at the time of purchase and re-evaluates the designations at each balance sheet date. The Company classifies marketable securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable securities not classified as cash equivalents that have remaining maturities of less than one year are classified as short-term marketable securities, and marketable securities with remaining maturities one year or greater are classified as long-term marketable securities. The cost of marketable securities sold is based on the specific identification method. In addition, interest income for marketable debt securities is recorded when earned using an effective yield method, giving effect to the amortization of premiums and accretion of discounts. The Company regularly reviews its marketable securities portfolio to determine if any security is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period any such determination is made. In making this judgment, the Company evaluates, among other things, the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company’s intent to sell, or whether it will more likely than not be required to sell, the security before recovery of its amortized cost basis. The Company’s assessment on whether a security is other-than-temporarily impaired could change in the future due to new developments or changes in assumptions related to any particular security.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are recorded on our consolidated balance sheets at outstanding amounts, less the allowance for doubtful accounts. The allowance for doubtful accounts is set at a level that represents our best estimate of the amount of probable credit losses in our existing accounts receivable balance. The allowance is based on various factors, including an assessment of the collectability of specific customer accounts. In circumstances where a specific customer’s inability to meet its financial obligations is known or expected, we record a specific provision for bad debts to reduce the receivable to the amount that we believe will be collected. Accounts receivable are written off against the allowance for doubtful accounts when an account is deemed to be uncollectible.
Inventories	Inventories Inventories are valued at lower of cost or market value. Cost includes all purchase, conversion, and other direct and indirect expenditures incurred in bringing the inventory to its existing condition and location. Wages and other related benefit costs of employees directly attributable to the production process and an allocated portion of other indirect production expenses (overhead) are included in inventory costs. Overhead includes both fixed and variable expenses which are allocated to inventory produced on a systematic basis. Cost is determined using the weighted average method. The Company regularly reviews inventory quantities on hand in consideration of projected future demand, product life cycles, design changes, and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.
Property and Equipment	Property and Equipment Property and equipment is stated at cost, less accumulated depreciation and amortization. Repairs and maintenance are charged to expense as incurred, while significant improvements are capitalized. Depreciation is computed using the straight-line method over the following estimated useful lives of the respective assets: Years Furniture and fixtures 7 Computers and software 2–5 Demonstration equipment 2 Machinery and equipment 7 Leasehold improvements are amortized over the lesser of the estimated useful life or lease term. Upon retirement or disposal of property and equipment, the related cost and accumulated depreciation are removed from the Company’s accounts, and any resulting gain or loss is recorded in the period of retirement or disposal.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment and intangible assets and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Factors that we consider in deciding when to perform an impairment review include significant under-performance of an asset in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use of the asset. If circumstances indicate potential impairment of a long-lived asset, the Company compares the undiscounted cash flows expected to be generated by the asset to the carrying amount of the asset. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. The Company determines fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value.
Goodwill	Goodwill Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets from the businesses that we acquire. The Company reviews goodwill for impairment annually, or more frequently if indicators of impairment exist. The annual impairment test is conducted as of September 30. The Company reviews goodwill for impairment by applying a quantitative impairment analysis using the two step method. Under the first step, the fair value of the reporting unit is compared with its carrying value (including goodwill). If the fair value of the reporting unit exceeds its carrying value, goodwill is not considered impaired, and we are not required to perform additional analysis. If the fair value of the reporting unit is less than its carrying value, the Company will recognize the amount of the impairment loss for any excess carrying amount of the reporting unit’s goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation, and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill.
Revenue Recognition	Revenue Recognition The Company generates revenue primarily from the sales of GI products and pathology services. The Company sells products through direct sales representatives in the U.S. and Germany and independent distributors in international markets. Sales to distributors are recorded when title and risk of loss transfer. No direct sales customers or distributors have price protection. We recognize revenue when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) delivery obligations to the customer related to the products or services have been satisfied; (3) the arrangement consideration is fixed or determinable; and (4) the collection of the revenues is reasonably assured. GI pathology service revenue is recognized as services are performed, net of estimated reimbursement adjustments by payors. These adjustments include contractual write-downs under health insurance contracts, rebates for billing errors, and out-of-network charges. These estimates are based on the terms of contracts with health insurance payors and historical collections experience. Revenue from endoscope repair services, included in GI equipment and supplies revenue, are recognized ratably over the life of the contract. Deferred revenue is recorded for consideration received that is not yet earned due to outstanding obligations related to sales of products and services. The Company’s policy is to classify shipping and handling costs billed to customers as revenues and the related expenses as costs of revenues. Sales taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and, therefore, are excluded from revenues in the consolidated statements of comprehensive loss.
Cost of Revenues	Cost of Revenues Cost of revenues consist primarily of manufacturing overhead costs, direct material costs, and direct labor. A significant portion of our cost of revenues consists of manufacturing overhead costs, which include the cost of quality assurance, material procurement, inventory control, warehousing and shipment, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for production equipment and certain direct costs such as shipping costs.
Research and Development	Research and Development Research and development costs, including new product development, regulatory compliance and clinical research, are charged to operations as incurred in the consolidated statements of operations and comprehensive loss. Such costs include personnel-related costs, supplies, services, depreciation, allocated facilities overhead and information services, clinical trial and related clinical manufacturing expenses, fees paid to investigative sites and other indirect costs.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation awards to employees and directors in accordance with the provisions of Accounting Standards Codification 718, Compensation — Stock Compensation. The Company measures stock-based compensation cost at grant date based on the estimated fair value of the award and recognizes the cost of awards expected to vest over the requisite service period. The fair value of restricted stock awards is determined based on the closing price of the Company’s stock on the grant date. The fair value of stock option awards and employee stock purchase plan grants are determined on the grant date using the Black-Scholes-Merton option-pricing model (“Black-Scholes model”). The determination of fair value on the grant date using the Black-Scholes model is affected by the Company's stock price as well as assumptions regarding a number of subjective variables. These variables include but are not limited to the expected dividend yield, expected volatility over the term of the award, risk-free interest rate, expected term, and the actual and projected employee option exercise behavior. Expected dividend yield: A zero percent dividend yield is assumed as the Company has not paid and does not expect to pay dividends on common stock. Expected volatility: Volatility is estimated for each stock option grant based on a study of publicly traded industry peer companies. In evaluating similarity, the Company considered factors such as industry, stage of development, and size. Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for zero-coupon U.S. Treasury notes with remaining terms similar to the expected term of the options. Expected term: The expected term represents the period that option awards are expected to be outstanding. Due to our limited trading history as a public company as well as limitations on the sale or transfer of stock-based compensation awards granted prior to the initial public offering discussed in Note 1, we do not believe our historical exercise pattern is indicative of the pattern that we will experience as a publicly traded company. We have consequently used the simplified method available under Staff Accounting Bulletin ("SAB) 110 to calculate the expected term, which utilizes the midpoint between the vesting date and the end of the contractual term.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In the event the future tax consequences of differences between the financial reporting bases and the tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation of the probability of being able to realize the future benefits indicated by such assets is required. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some or all of the deferred tax asset will not be realized. In assessing the realizability of the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable earnings, and tax planning strategies. The income tax benefit or expense is the total current year income tax due or refundable and the change in deferred tax assets and liabilities. A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of the tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Other comprehensive income (loss) refers to revenues, expenses, gains, and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings, as these amounts are recorded directly as an adjustment to stockholders’ equity. Other comprehensive income (loss) is comprised of foreign currency translation adjustments and unrealized gains (losses) on available-for-sale marketable securities. These amounts are presented in the consolidated statements of operations and comprehensive loss and redeemable members' capital and stockholders’ equity/members' deficit.
Fair Value	Fair Value Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date under current market conditions. The Company categorizes its financial assets and liabilities into a three-level hierarchy based on the priority of the inputs to the valuation, pursuant to the Fair Value Measurements and disclosures of ASC Topic 820. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the overall fair value measurement of the instrument. Level 1 – Quoted prices available in active markets for identical investments as of the reporting date; Level 2 – Inputs other than quoted prices for identical assets or liabilities in active markets that are either directly or indirectly observable as of the reporting date; and, Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the asset or liability. These inputs reflect management judgment about the assumptions that market participants would use in valuing the asset or liability.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period. Stock options, warrants, and restricted shares are considered to be common stock equivalents and are evaluated for dilutive effect using the treasury-stock method. Basic and diluted net loss per common share are the same for years ended December 31, 2015, 2014, and 2013 due to the Company's reported net losses during those periods and the exclusion of dilutive common stock equivalents from diluted weighted-average shares of common stock outstanding.
Adoption of New Accounting Pronouncements	Adoption of New Accounting Pronouncements In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-17, Balance Sheet Classification of Deferred Taxes, requiring all deferred tax assets and liabilities, and any related valuation allowances, to be classified as non-current on the balance sheet. The standard is effective for reporting periods beginning after December 15, 2016 and interim periods within those fiscal years, and early adoption is permitted. ASU 2015-17 may be applied either prospectively to all deferred tax assets and liabilities or retrospectively to all periods presented. The guidance was early adopted in the fourth quarter of 2015, as permitted, on a prospective basis. The adoption affected only the presentation of deferred taxes on the consolidated balance sheets and had no impact on the Company's results of operations. In April 2015, the FASB issued ASU 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 will require an entity to present debt issuance costs in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than as an asset, consistent with the treatment of debt discounts. The amendment does not change the recognition and measurement guidance for debt issuance costs, and the amortization of debt issuance costs will continue to be reported as interest expense. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2016. The Company early adopted ASU 2015-03 in June 2015, as permitted, and applied the new guidance retrospectively to the consolidated balance sheet as of December 31, 2014. There was no impact from the early adoption of ASU 2015-03 on the Company's results of operations. December 31, 2014 Prior to Adoption of ASU 2015-03 Effect of Adoption As Adopted Prepaid expenses and other current assets $ 2,774 $ (411 ) $ 2,363 Total current assets 39,521 (411 ) 39,110 Total assets 87,220 (411 ) 86,809 Long-term debt $ 39,350 $ (411 ) $ 38,939 Total liabilities 60,981 (411 ) 60,570 Future Adoption of Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is in the process of evaluating the impact of this new guidance. In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016-01 is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company is currently evaluating the impact of the future adoption of this standard, but the adoption is not expected to have a material effect on the consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. ASU 2015-11 changes the measurement principle for inventory for entities using FIFO or average cost from the lower of cost or market to lower of cost and net realizable value. ASU 2015-11 defines net realizable value as estimated selling prices in the ordinary course of business less reasonably predictable costs of completion, disposal, and transportation. The standard is effective for reporting periods beginning after December 15, 2016 and interim periods within those fiscal years with early adoption permitted. ASU 2015-11 should be applied prospectively. The Company is currently evaluating the impact of the future adoption of this standard, but the adoption is not expected to have a material effect on the consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern at each annual and interim period. Related footnote disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year after the report issuance date. If conditions do not give rise to substantial doubt, no disclosures will be required specific to going concern uncertainties. The ASU defines substantial doubt using a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies and provides example indicators. ASU 2014-15 is effective for reporting periods ending after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the future adoption of this standard, but the adoption is not expected to have a material effect on the consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosures about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09, as specified in ASU 2015-14, is now effective for reporting periods beginning after December 15, 2017. Earlier adoption is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. We are currently evaluating the impact of the future adoption of this standard.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Property and Equipment	Depreciation is computed using the straight-line method over the following estimated useful lives of the respective assets: Years Furniture and fixtures 7 Computers and software 2–5 Demonstration equipment 2 Machinery and equipment 7 Property and equipment consisted of the following: December 31, 2015 2014 Furniture and fixtures $ 1,229 $ 925 Leasehold improvements 2,244 2,053 Computers and software 3,245 2,864 Demonstration equipment 8,414 6,553 Machinery and equipment 6,428 3,666 Construction in progress 1,015 — Total 22,575 16,061 Accumulated depreciation (11,052 ) (6,393 ) Property and equipment, net $ 11,523 $ 9,668

Adoption of New Accounting Pr27

Adoption of New Accounting Pronouncements (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncement, Early Adoption	December 31, 2014 Prior to Adoption of ASU 2015-03 Effect of Adoption As Adopted Prepaid expenses and other current assets $ 2,774 $ (411 ) $ 2,363 Total current assets 39,521 (411 ) 39,110 Total assets 87,220 (411 ) 86,809 Long-term debt $ 39,350 $ (411 ) $ 38,939 Total liabilities 60,981 (411 ) 60,570

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	For the Company’s assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3), the following table provides a reconciliation of the beginning and ending balances for each category therein and gains or losses recognized during the period: Fair value measurements using significant unobservable inputs (level 3): Contingent liabilities for accrued earn-out acquisition consideration Warrants Balance as of January 1, 2014 $ 673 $ — Foreign currency translation adjustments (41 ) — Issuance of warrants — 650 Balance as of December 31, 2014 632 650 Foreign currency translation adjustments (31 ) — Remeasurement to fair value (208 ) 435 Reclassification from other long-term liabilities to additional paid-in-capital — (1,085 ) Balance as of December 31, 2015 $ 393 $ —

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	The table below summarizes the Company’s available-for-sale marketable securities' amortized cost, gross unrealized gains, gross unrealized losses, and fair value by significant investment category recorded as short-term marketable securities or long-term marketable securities as of December 31, 2015 (refer to Note 2 for discussion of our fair value hierarchy). The Company had no marketable securities as of December 31, 2014. Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term Marketable Securities Long-term Marketable Securities Level 1: U.S. Treasuries $ 4,017 $ — $ (10 ) $ 4,007 $ 2,004 $ 2,003 U.S. government agencies 3,656 — (9 ) 3,647 1,556 2,091 Subtotal 7,673 — (19 ) 7,654 3,560 4,094 Level 2: Commercial paper 3,998 — — 3,998 3,998 — Corporate securities 42,065 1 (98 ) 41,968 26,314 15,654 Subtotal 46,063 1 (98 ) 45,966 30,312 15,654 Total $ 53,736 $ 1 $ (117 ) $ 53,620 $ 33,872 $ 19,748
Investments Classified by Contractual Maturity Date	The amortized cost and fair value of short-term and long-term marketable securities as of December 31, 2015 are shown below by contractual maturity. Actual maturities may differ from contractual maturities as securities may be restructured, called, or prepaid. Amortized Cost Fair Value Due to mature: Less than one year $ 33,929 $ 33,872 One to two years 19,807 19,748 Total $ 53,736 $ 53,620

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories consisted of the following: December 31, 2015 2014 Raw materials $ 6,821 $ 4,428 Work-in-process 3,113 3,282 Finished goods 7,539 5,927 Total inventories $ 17,473 $ 13,637

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Depreciation is computed using the straight-line method over the following estimated useful lives of the respective assets: Years Furniture and fixtures 7 Computers and software 2–5 Demonstration equipment 2 Machinery and equipment 7 Property and equipment consisted of the following: December 31, 2015 2014 Furniture and fixtures $ 1,229 $ 925 Leasehold improvements 2,244 2,053 Computers and software 3,245 2,864 Demonstration equipment 8,414 6,553 Machinery and equipment 6,428 3,666 Construction in progress 1,015 — Total 22,575 16,061 Accumulated depreciation (11,052 ) (6,393 ) Property and equipment, net $ 11,523 $ 9,668

Goodwill and Other Intangible32

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for amortizable intangible assets as of December 31, 2015 and December 31, 2014 are as follows: December 31, 2015 December 31, 2014 Gross carrying amount Accumulated amortization Net carrying value Gross carrying amount Accumulated amortization Net carrying value Amortizable intangible assets: Customer relationships $ 1,683 $ (732 ) $ 951 $ 1,845 $ (595 ) $ 1,250 Developed technology 20,498 (7,687 ) 12,811 20,435 (5,109 ) 15,326 Other intangible assets 2,198 (2,141 ) 57 2,203 (2,124 ) 79 Total amortizable intangible assets $ 24,379 $ (10,560 ) $ 13,819 $ 24,483 $ (7,828 ) $ 16,655 Unamortizable intangible assets: Goodwill $ 20,105 $ — $ 20,105 $ 20,301 $ — $ 20,301
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	As of December 31, 2015, estimated aggregate future amortization expense for the intangible assets is as follows: Estimated amortization expenses: 2016 $ 2,735 2017 2,735 2018 2,735 2019 2,735 2020 2,721 Thereafter 158 Total $ 13,819
Schedule of Goodwill	Changes in the carrying amount of amortizable intangible assets and goodwill for the years ended December 31, 2015 and 2014 are as follows: Amortizable intangible assets: Balance at December 31, 2014 $ 16,655 Amortization (2,753 ) Foreign currency translation adjustment (83 ) Balance at December 31, 2015 $ 13,819 Goodwill: Balance at December 31, 2014 20,301 Foreign currency translation adjustment (196 ) Balance at December 31, 2015 $ 20,105
Schedule of Finite-Lived Intangible Assets	Changes in the carrying amount of amortizable intangible assets and goodwill for the years ended December 31, 2015 and 2014 are as follows: Amortizable intangible assets: Balance at December 31, 2014 $ 16,655 Amortization (2,753 ) Foreign currency translation adjustment (83 ) Balance at December 31, 2015 $ 13,819 Goodwill: Balance at December 31, 2014 20,301 Foreign currency translation adjustment (196 ) Balance at December 31, 2015 $ 20,105

Accrued Expenses and Other Cu33

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses and other current liabilities consisted of the following: December 31, 2015 2014 Payroll and employee related expenses $ 4,787 $ 4,293 Accrued warranty costs 922 207 Sales and other taxes payable 320 438 Other accrued liabilities 3,174 3,390 Accrued expenses and other current liabilities $ 9,203 $ 8,328

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt	As of December 31, 2015, the outstanding debt repayment schedule is as follows: 2018 $ 17,200 2019 17,200 2020 8,600 Principal amounts repayable 43,000 Unamortized debt discount (357 ) Total long-term debt, net of discount $ 42,643

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contractual Obligation, Fiscal Year Maturity Schedule	Future minimum lease payments under noncancelable operating leases at December 31, 2015 are as follows: Amount Year: 2016 $ 1,610 2017 1,714 2018 1,494 2019 1,466 2020 956 Thereafter 1,183 Total $ 8,423

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	Following is a summary of stock option activity for the year ended December 31, 2015: Number of Options Weighted average exercise price Weighted average remaining contractual term Aggregate Intrinsic Value Outstanding at December 31, 2014 341,345 $ 2.30 5.2 years Granted 578,713 15.89 Exercised (41,455 ) 8.11 Forfeited (30,203 ) 15.54 Outstanding at December 31, 2015 848,400 11.10 7.7 years $ 1,804 Vested and expected to vest at December 31, 2015 781,400 10.70 7.5 years 1,804 Vested and exercisable at December 31, 2015 304,745 $ 2.58 4.2 years $ 1,804
Nonvested Restricted Stock Shares Activity	Following is a summary of the restricted stock activity for the year ended December 31, 2015: Number of Restricted Stock Shares Weighted-Average Grant-Date Fair Value Unvested at December 31, 2014 715,577 $ 3.28 Granted 798,153 15.92 Vested (366,722 ) 4.33 Forfeited (63,215 ) 11.14 Unvested at December 31, 2015 1,083,793 $ 12.39
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	We recognized stock-based compensation expense as follows for the years ended December 31, 2015, 2014, and 2013: Years Ended December 31, 2015 2014 2013 Cost of revenues $ 143 $ — $ — Research and development 623 4 5 Sales and marketing 688 4 5 General and administrative 3,774 12 14 Total $ 5,228 $ 20 $ 24
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company’s stock-based compensation plans and rights to acquire stock granted under the Company’s ESPP. The weighted average estimated fair values of stock options, the rights to acquire stock granted, and the weighted average assumptions used in calculating those fair values were as follows: Years Ended December 31, 2015 2014 2013 Stock Options Risk free interest rate 1.6 % — % — % Expected term (in years) 5.0 0 0 Expected volatility 45.0 % — % — % Dividend yield — % — % — % Weighted average fair value at grant date $ 6.38 $ — $ — Employee Stock Purchase Plan Risk free interest rate 0.1 % — % — % Expected term (in years) 0.5 0 0 Expected volatility 47.0 % — % — % Dividend yield — % — % — % Weighted average fair value at grant date $ 4.65 $ — $ —
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions	The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company’s stock-based compensation plans and rights to acquire stock granted under the Company’s ESPP. The weighted average estimated fair values of stock options, the rights to acquire stock granted, and the weighted average assumptions used in calculating those fair values were as follows: Years Ended December 31, 2015 2014 2013 Stock Options Risk free interest rate 1.6 % — % — % Expected term (in years) 5.0 0 0 Expected volatility 45.0 % — % — % Dividend yield — % — % — % Weighted average fair value at grant date $ 6.38 $ — $ — Employee Stock Purchase Plan Risk free interest rate 0.1 % — % — % Expected term (in years) 0.5 0 0 Expected volatility 47.0 % — % — % Dividend yield — % — % — % Weighted average fair value at grant date $ 4.65 $ — $ —

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	After giving effect to the corporate conversion as described in Note 1, the following table provides a reconciliation of the numerator and denominator used in calculating basic and diluted net loss per share attributable to common stockholders for the years ended December 31, 2015, 2014, and 2013, respectively. Years Ended December 31, 2015 2014 2013 Numerator: Net loss attributable to common stockholders $ (59,384 ) $ (53,644 ) $ (23,918 ) Denominator: Weighted-average common shares outstanding - basic 21,076,246 12,482,988 12,044,447 Dilutive effect of stock options, warrants, and restricted stock units¹ — — — Weighted-average common shares outstanding - diluted 21,076,246 12,482,988 12,044,447 Net loss per share attributable to common stockholders - basic and diluted $ (2.82 ) $ (4.30 ) $ (1.99 ) ¹Potentially dilutive stock options, warrants, and restricted stock were excluded from the calculation of diluted weighted-average shares outstanding as they would have had an anti-dilutive effect due to losses reported during the years ended December 31, 2015, 2014, and 2013.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The treasury stock method is used to determine the dilutive effect of the Company’s potentially dilutive securities. The following securities were excluded from the calculation of diluted shares outstanding due to their anti-dilutive effect: December 31, 2015 2014 2013 Stock options 848,400 341,345 391,526 Warrants for common stock 4,061 187,161 4,061 Restricted stock 1,083,793 — — Total 1,936,254 528,506 395,587

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	For the years ended December 31, 2015, 2014, and 2013, net loss before income taxes consists of the following: 2015 2014 2013 U.S. operations $ (57,726 ) $ (57,444 ) $ (14,458 ) Foreign operations (2,019 ) 4,716 (11,018 ) $ (59,745 ) $ (52,728 ) $ (25,476 )
Schedule of Components of Income Tax Expense (Benefit)	Income tax benefit (expense) attributable to net loss consists of the following for the years ended December 31, 2015, 2014, and 2013: Current Deferred Total Year ended December 31, 2015: U.S. federal $ — $ — $ — State and local (13 ) — (13 ) Foreign jurisdiction — 374 374 $ (13 ) $ 374 $ 361 Year ended December 31, 2014: U.S. federal $ — $ — $ — State and local (8 ) — (8 ) Foreign jurisdiction (18 ) (890 ) (908 ) $ (26 ) $ (890 ) $ (916 ) Year ended December 31, 2013: U.S. federal $ — $ — $ — State and local (38 ) — (38 ) Foreign jurisdictions — 1,596 1,596 $ (38 ) $ 1,596 $ 1,558
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective income tax rate for the years ended December 31, 2015, 2014 and 2013 is as follows: 2015 2014 2013 Tax at statutory rate 34.00 % 34.00 % 34.00 % State taxes 10.64 % 2.64 % 1.55 % Other/permanent items (2.63 )% (0.28 )% (2.58 )% Foreign rate differential (0.22 )% 0.60 % (2.81 )% Change in valuation allowance (41.19 )% (38.68 )% (23.96 )% Effective tax rate 0.60 % (1.72 )% 6.20 %
Schedule of Deferred Tax Assets and Liabilities	The following table summarizes the significant components of our deferred tax assets and liabilities as of December 31, 2015 and 2014: 2015 2014 Deferred tax assets: Accounts receivable, principally due to allowance for doubtful accounts $ 334 $ 310 Inventories 521 370 Compensated absences, principally due to accrual for financial reporting purposes 244 300 Compensated bonuses, principally due to accrual for financial reporting purposes 465 411 Net operating loss carryforwards 52,065 30,465 Property and equipment, principally due to differences in depreciation 1,519 875 Other 1,311 658 Total gross deferred tax assets 56,459 33,389 Less valuation allowance (55,842 ) (32,212 ) Net deferred tax assets 617 1,177 Deferred tax liabilities: Intangibles (3,110 ) (4,038 ) Other — (316 ) Total gross deferred liabilities (3,110 ) (4,354 ) Net deferred tax liability $ (2,493 ) $ (3,177 )

Segment, Geographical, and Cu39

Segment, Geographical, and Customer Concentration (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Revenue from External Customers by Geographic Areas	The following table represents net revenues by geographic area based on the location of the customer during the years ended December 31, 2015, 2014, and 2013: Years Ended 2015 2014 2013 United States $ 64,675 $ 54,570 $ 45,457 International 7,625 6,849 5,434 Total $ 72,300 $ 61,419 $ 50,891
Long-lived Assets by Geographic Areas	The composition of the Company’s long-lived assets, consisting of property and equipment, amortizable intangible assets, and goodwill by geographic area is set forth below: December 31, 2015 2014 United States $ 7,694 $ 6,516 Israel 31,694 33,855 Other Regions 6,059 6,253 Total $ 45,447 $ 46,624

Selected Quarterly Financial 40

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Selected Quarterly Financial Data (Unaudited) Quarter Ended March 31 June 30 September 30 December 31 (In thousands, except per share data) Year Ended December 31, 2015 Net revenues $ 16,748 $ 18,642 $ 18,363 $ 18,547 Gross profit 5,579 6,533 6,141 5,057 Operating loss (12,451 ) (14,824 ) (10,443 ) (12,538 ) Net loss (15,274 ) (19,487 ) (11,578 ) (13,045 ) Net loss per share attributable to common stockholders, basic and diluted¹ $ (1.00 ) $ (1.01 ) $ (0.47 ) $ (0.53 ) Year Ended December 31, 2014 Net revenues $ 13,847 $ 15,081 $ 14,169 $ 18,322 Gross profit 6,394 5,291 5,791 5,035 Operating loss (10,138 ) (12,566 ) (11,710 ) (12,801 ) Net loss (10,878 ) (13,708 ) (14,027 ) (15,031 ) Net loss per share attributable to common stockholders, basic and diluted¹ $ (0.90 ) $ (1.13 ) $ (1.16 ) $ (1.10 ) ¹Net loss per share is calculated independently for each quarter presented. Therefore, the sum of the quarterly net loss per share amounts will not necessarily equal the total for the year.

Description of Business and B41

Description of Business and Background (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 10, 2015	Jun. 04, 2015	Jan. 04, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2015
Business Acquisition [Line Items]
Additional capital from private equity sources			$ 44,286
Aggregate number of options shareholders have (in shares)		339,373		848,400	341,345
Proceeds from issuance of common stock in initial public offering, net of issuance costs				$ 94,186	$ 0	$ 0
Common Stock [Member]
Business Acquisition [Line Items]
Shares available for conversion (in shares)		17,580,918
Warrant [Member]
Business Acquisition [Line Items]
Aggregate amount of convertible securities (in shares)		187,161
IPO [Member]
Business Acquisition [Line Items]
Proceeds from issuance of common stock in initial public offering, net of issuance costs	$ 94,186
Payment for underwriting discounts and commissions	7,405
offering expenses	$ 4,197
IPO [Member] | Common Stock [Member]
Business Acquisition [Line Items]
IPO shares (in shares)	7,302,500
Shares issued in IPO (in shares)	7,052,500
Shares sold in the IPO by existing stockholders (in shares)	250,000
Over-Allotment Option [Member] | Common Stock [Member]
Business Acquisition [Line Items]
IPO shares (in shares)	952,500
Restricted Stock [Member]
Business Acquisition [Line Items]
Shares available for conversion (in shares)		579,869
Underwriter Option [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Price of shares sold to underwriter (in usd per share)	$ 15
Affiliated Entity [Member] | ECPM Holdings, LLC [Member]
Business Acquisition [Line Items]
Percentage ownership			100.00%
Revolving Credit Facility [Member]
Business Acquisition [Line Items]
Capital under revolving line of credit							$ 15,000

Summary of Significant Accoun42

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash and Cash Equivalents [Line Items]
Foreign currency gains (losses) recorded in other income (expense) in the consolidated statements of comprehensive loss	$ (1,521,000)	$ (1,027,000)	$ 202,000
Provision for doubtful accounts	979,000	466,000	992,000
Allowance for doubtful accounts	940,000	860,000
Impairment charges	1,070,000	0	0
Allowance for estimated warranty claims	922,000	207,000
Research and development, labor and overhead	1,345,000	3,422,000	5,749,000
Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Investments in money market funds classified as cash equivalents	$ 16,104,000	0
Furniture and Fixtures [Member]
Cash and Cash Equivalents [Line Items]
PP&E useful life	7 years
Demonstration Equipment [Member]
Cash and Cash Equivalents [Line Items]
PP&E useful life	2 years
Impairment charges	$ 1,029,000	$ 0	$ 0
Machinery and Equipment [Member]
Cash and Cash Equivalents [Line Items]
PP&E useful life	7 years
Minimum [Member] | Computers And Software [Member]
Cash and Cash Equivalents [Line Items]
PP&E useful life	2 years
Maximum [Member] | Computers And Software [Member]
Cash and Cash Equivalents [Line Items]
PP&E useful life	5 years
EndoChoice Israel, Ltd. [Member]
Cash and Cash Equivalents [Line Items]
Percentage of ownership	67.00%

Adoption of New Accounting Pr43

Adoption of New Accounting Pronouncements (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
New Accounting Pronouncement, Early Adoption [Line Items]
Prepaid expenses and other current assets	$ 3,108	$ 2,363
Total current assets	98,366	39,110
Total assets	164,338	86,809
Long-term debt	42,643	38,939
Total liabilities	$ 65,045	60,570
Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Prepaid expenses and other current assets		2,363
Total current assets		39,110
Total assets		86,809
Long-term debt		38,939
Total liabilities		60,570
Accounting Standards Update 2015-03 [Member] | New Accounting Pronouncement, Early Adoption, Effect [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Prepaid expenses and other current assets		(411)
Total current assets		(411)
Total assets		(411)
Long-term debt		(411)
Total liabilities		(411)
Accounting Standards Update 2015-03 [Member] | Scenario, Previously Reported [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Prepaid expenses and other current assets		2,774
Total current assets		39,521
Total assets		87,220
Long-term debt		39,350
Total liabilities		$ 60,981

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jun. 04, 2015	Jun. 03, 2015
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Number of warrants (in shares)				183,100	2,091,175
Warrant exercise price (in usd per share)				$ 10.95	$ 0.96
Change in fair value of warrant liability	$ 435	$ 0	$ 0
Other Expense [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Change in fair value of warrant liability	435
Accrued Expenses And Other Current Liabilities [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent liabilities for accrued-earnout acquisition consideration in other current liabilities	110
Other Long-Term Liabilities [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Contingent liabilities for accrued-earnout acquisition consideration in other long-term liabilities	$ 283

Fair Value Measurements (Deta45

Fair Value Measurements (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Contingent liabilities For Accrued Earn-Out Acquisition Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 632	$ 673
Foreign currency translation adjustments	(31)	(41)
Remeasurement to fair value	208
Ending balance	393	632
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	650	0
Issuance of warrants		650
Remeasurement to fair value	435
Reclassification from other long-term liabilities to additional paid-in-capital	(1,085)
Ending balance	$ 0	$ 650

Marketable Securities Summary o

Marketable Securities Summary of Available-for-Sale Securities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 53,736,000
Gross Unrealized Gains	1,000
Gross Unrealized Losses	(117,000)
Fair Value	53,620,000	$ 0
Short-term Marketable Securities	33,872,000
Long-term Marketable Securities	19,748,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	7,673,000
Gross Unrealized Gains	0
Gross Unrealized Losses	(19,000)
Fair Value	7,654,000
Short-term Marketable Securities	3,560,000
Long-term Marketable Securities	4,094,000
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	4,017,000
Gross Unrealized Gains	0
Gross Unrealized Losses	(10,000)
Fair Value	4,007,000
Short-term Marketable Securities	2,004,000
Long-term Marketable Securities	2,003,000
Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	3,656,000
Gross Unrealized Gains	0
Gross Unrealized Losses	(9,000)
Fair Value	3,647,000
Short-term Marketable Securities	1,556,000
Long-term Marketable Securities	2,091,000
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	46,063,000
Gross Unrealized Gains	1,000
Gross Unrealized Losses	(98,000)
Fair Value	45,966,000
Short-term Marketable Securities	30,312,000
Long-term Marketable Securities	15,654,000
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	3,998,000
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	3,998,000
Short-term Marketable Securities	3,998,000
Long-term Marketable Securities	0
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	42,065,000
Gross Unrealized Gains	1,000
Gross Unrealized Losses	(98,000)
Fair Value	41,968,000
Short-term Marketable Securities	26,314,000
Long-term Marketable Securities	$ 15,654,000

Marketable Securities Amortized

Marketable Securities Amortized Cost and Fair Value of Short-Term and Long-Term Investments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Investments, Debt and Equity Securities [Abstract]
Less than one year, Amortized Cost	$ 33,929
One to two years, Amortized Cost	19,807
Total, Amortized Cost	53,736
Less than one year, Fair Value	33,872
One to two years, Fair Value	19,748
Total, Fair Value	53,620
Unrealized gains net of tax	$ 116

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 6,821	$ 4,428
Work-in-process	3,113	3,282
Finished goods	7,539	5,927
Inventory, Net	$ 17,473	$ 13,637

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment	$ 22,575,000	$ 16,061,000
Accumulated depreciation	(11,052,000)	(6,393,000)
Property and equipment, net	11,523,000	9,668,000
Depreciation expense	5,533,000	4,849,000	$ 1,412,000
Loss on impairment of property and equipment	1,070,000	0	0
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,229,000	925,000
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	2,244,000	2,053,000
Computers And Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	3,245,000	2,864,000
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	8,414,000	6,553,000
Loss on impairment of property and equipment	1,029,000	0	$ 0
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	6,428,000	3,666,000
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 1,015,000	$ 0

Goodwill and Other Intangible50

Goodwill and Other Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Amortizable intangible assets:
Amortizable intangible assets, Gross carrying amount	$ 24,379	$ 24,483
Amortizable intangible assets, Accumulated amortization	(10,560)	(7,828)
Amortizable intangible assets, Net carrying value	13,819	16,655
Unamortizable intangible assets:
Goodwill, Gross carrying amount	20,105	20,301
Goodwill, Impaired, Accumulated Impairment Loss	0	0
Goodwill	20,105	20,301
Customer Relationships [Member]
Amortizable intangible assets:
Amortizable intangible assets, Gross carrying amount	1,683	1,845
Amortizable intangible assets, Accumulated amortization	(732)	(595)
Amortizable intangible assets, Net carrying value	951	1,250
Developed Technology Rights [Member]
Amortizable intangible assets:
Amortizable intangible assets, Gross carrying amount	20,498	20,435
Amortizable intangible assets, Accumulated amortization	(7,687)	(5,109)
Amortizable intangible assets, Net carrying value	12,811	15,326
Other Intangible Assets [Member]
Amortizable intangible assets:
Amortizable intangible assets, Gross carrying amount	2,198	2,203
Amortizable intangible assets, Accumulated amortization	(2,141)	(2,124)
Amortizable intangible assets, Net carrying value	$ 57	$ 79

Goodwill and Other Intangible51

Goodwill and Other Intangible Assets (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 2,753	$ 3,908	$ 4,578
2,016	2,735
2,017	2,735
2,018	2,735
2,019	2,735
2,020	2,721
Thereafter	158
Amortizable intangible assets, Net carrying value	$ 13,819	$ 16,655

Goodwill and Other Intangible52

Goodwill and Other Intangible Assets (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets, beginning	$ 16,655
Amortization	(2,753)	$ (3,908)	$ (4,578)
Foreign currency translation adjustment, intangible assets	(83)
Finite-lived intangible assets, ending	13,819	16,655
Goodwill [Roll Forward]
Goodwill, beginning	20,301
Foreign currency translation adjustment, goodwill	(196)
Goodwill, ending	$ 20,105	$ 20,301

Accrued Expenses and Other Cu53

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Payroll and employee related expenses	$ 4,787	$ 4,293
Accrued warranty costs	922	207
Sales and other taxes payable	320	438
Other accrued liabilities	3,174	3,390
Accrued expenses and other current liabilities	$ 9,203	$ 8,328

Debt (Details)

Debt (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Long-term debt, net of discount		$ 42,643,000	$ 38,939,000
Outstanding debt prepaid		40,000,000	0	$ 0
Prepayment and end of term fees		2,306,000	0	0
Loss on early retirement of debt		2,282,000	0	0
End of term fee		1,269,000
Secured Debt [Member] | Term Loan Facility [Member]
Debt Instrument [Line Items]
Loan agreement term	5 years
Loan facility face amount	$ 43,000,000
Stated interest rate	9.50%
End of term loan fee	2.95%
Interest only period for term loan	30 months
Debt issuance cost	$ 417,000
Triple Point Capital, LLC [Member] | Secured Debt [Member] | Growth Capital Facility [Member]
Debt Instrument [Line Items]
Outstanding debt prepaid	40,000,000
Prepayment and end of term fees	2,306,000
Payments other fees and expenses in connection with the refinancing	517,000
Loss on early retirement of debt			$ 0	$ 0
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Revolving credit facility amount	15,000,000
Long term revolving credit facility	$ 0
Revolving Credit Facility [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Loan agreement term	5 years
London Interbank Offered Rate (LIBOR) [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Revolving credit facility spread	5.25%
Revolving credit facility unused line fee	0.50%
Other Long-Term Liabilities [Member]
Debt Instrument [Line Items]
End of term fee accrual		$ 118,000

Debt - Repayment Schedule (Deta

Debt - Repayment Schedule (Details) $ in Thousands	Dec. 31, 2015USD ($)
Debt Disclosure [Abstract]
2,018	$ 17,200
2,019	17,200
2,020	8,600
Principal amounts repayable	43,000
Unamortized debt discount	(357)
Total long-term debt, net of discount	$ 42,643

Commitments and Contingencies56

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Rent expense for operating lease	$ 1,359	$ 1,188	$ 848
2,016	1,610
2,017	1,714
2,018	1,494
2,019	1,466
2,020	956
Thereafter	1,183
Total	$ 8,423

Stock-based Compensation (Detai

Stock-based Compensation (Details)	Jun. 04, 2015shares	Jun. 30, 2015USD ($)shares	Jun. 30, 2015empolyee	Dec. 31, 2015USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2015USD ($)shares	May. 07, 2015USD ($)	May. 06, 2015USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value at grant date (in usd per share) | $ / shares						$ 6.38
Number of options granted (in shares)						578,713	0	0
Unrecognized compensation cost related to stock options | $				$ 2,953,000	$ 2,953,000	$ 2,953,000			$ 2,953,000
Weighted average period of compensation cost recognition						3 years 6 months 24 days
Aggregate pre-tax intrinsic value of stock options exercised | $						$ 456,000	$ 326,000	$ 38,000
Proceeds from option exercises | $						$ 96,000	$ 5,000	$ 135,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for conversion (in shares)	17,580,918
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value at grant date (in usd per share) | $ / shares						$ 6.38	$ 0	$ 0
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value at grant date (in usd per share) | $ / shares						$ 4.65	0	0
Employee Stock [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP payroll deduction percentage		15.00%	15.00%
ESPP share purchase limitation (in shares)		5,000
ESPP purchase limitation market value of common shares | $		$ 25,000
Shares of stock issued (in shares)						55,076
Stock-based compensation expense | $						$ 165,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted (in shares)						798,153
Shares available for conversion (in shares)	579,869
Weighted average period of compensation cost recognition						3 years 1 month 24 days
Weighted average grant date fair value of shares granted (in usd per share) | $ / shares						$ 15.92	$ 5.53	$ 2.69
Fair value of restricted stock vested | $						$ 5,339,000
Number of Restricted Stock Shares, Vested (in shares)						366,722	0	0
Unrecognized compensation cost related to the restricted stock | $				$ 9,464,000	$ 9,464,000	$ 9,464,000			$ 9,464,000	$ 5,160,000	$ 2,353,000
Share based compensation expense, previously unrecognized | $						$ 3,496,000
Restricted stock vesting period						4 years
2015 Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award shares authorized (in shares)				1,260,664	1,260,664	1,260,664			1,260,664
Percentage increase in issued shares by outstanding shares				4.00%	4.00%	4.00%			4.00%
2015 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)					578,713
2015 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted (in shares)					649,067
2013 Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for conversion (in shares)	274,808
2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted (in shares)				497,323
Shares available for conversion (in shares)	579,869								579,869
2013 Plan [Member] | Incentive Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for conversion (in shares)						149,086
Employee And Non-Employee Directors [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of employees for incentive unit grants | empolyee			55

Stock-based Compensation (Det58

Stock-based Compensation (Details 2) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options outstanding, beginning balance (in shares)	341,345
Number of options granted (in shares)	578,713	0	0
Number of options exercised (in shares)	(41,455)
Number of options forfeited (in shares)	(30,203)
Number of options outstanding, ending balance (in shares)	848,400	341,345
Number of options vested and expected to vest (in shares)	781,400
Number of options vested and exercisable (in shares)	304,745
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Options outstanding, Weighted average exercise price, beginning balance (in usd per share)	$ 2.30
Options granted, Weighted average exercise price (in usd per share)	15.89
Options exercised, Weighted average exercise price (in usd per share)	8.11
Options forfeited, Weighted average exercise price (in usd per share)	15.54
Options outstanding, Weighted average exercise price, ending balance (in usd per share)	11.10	$ 2.30
Options Vested and expected to vest, Weighted average exercise price (in usd per share)	10.70
Options vested and exercisable, Weighted average exercise price (in usd per share)	$ 2.58
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, Weighted average remaining contractual term	7 years 8 months 24 days	5 years 2 months 6 days
Options Vested and expected to vest, Weighted average remaining contractual term	7 years 5 months 24 days
Options Vested and exercisable, Weighted average remaining contractual term	4 years 2 months 24 days
Options Outstanding, Aggregate Intrinsic Value	$ 1,804
Options Vested and expected to vest, Aggregate Intrinsic Value	1,804
Options Vested and exercisable, Aggregate Intrinsic Value	$ 1,804

Stock-based Compensation (Det59

Stock-based Compensation (Details 3) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Restricted Stock Shares, beginning balance (in shares)	715,577
Number of Restricted Stock Shares, Granted (in shares)	798,153
Number of Restricted Stock Shares, Vested (in shares)	(366,722)	0	0
Number of Restricted Stock Shares, Forfeited (in shares)	(63,215)
Number of Restricted Stock Shares, ending balance (in shares)	1,083,793	715,577
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Number of Restricted Stock Shares, Weighted-Average Grant-Date Fair Value, beginning balance (in usd per share)	$ 3.28
Number of Restricted Stock Shares, Weighted-Average Grant-Date Fair Value, Granted (in usd per share)	15.92	$ 5.53	$ 2.69
Number of Restricted Stock Shares, Weighted-Average Grant-Date Fair Value, Vested (in usd per share)	4.33
Number of Restricted Stock Shares, Weighted-Average Grant-Date Fair Value, Forfeited (in usd per share)	11.14
Number of Restricted Stock Shares, Weighted-Average Grant-Date Fair Value, ending balance (in usd per share)	$ 12.39	$ 3.28

Stock-based Compensation (Det60

Stock-based Compensation (Details 4) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	$ 5,228	$ 20	$ 24
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	143	0	0
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	623	4	5
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	688	4	5
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	$ 3,774	$ 12	$ 14

Stock-based Compensation (Det61

Stock-based Compensation (Details 5) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value at grant date (in usd per share)	$ 6.38
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.60%	0.00%	0.00%
Expected term (in years)	5 years	0 years	0 years
Expected volatility	45.00%	0.00%	0.00%
Dividend yield	0.00%	0.00%	0.00%
Weighted average fair value at grant date (in usd per share)	$ 6.38	$ 0	$ 0
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.10%	0.00%	0.10%
Expected term (in years)	6 months	0 years	0 years
Expected volatility	47.00%	0.00%	0.00%
Dividend yield	0.00%	0.00%	0.00%
Weighted average fair value at grant date (in usd per share)	$ 4.65	$ 0	$ 0

Net Loss per Common Share (Deta

Net Loss per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended																12 Months Ended
		Dec. 31, 2015		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net loss attributable to common stockholders		$ (13,045)		$ (11,578)		$ (19,487)		$ (15,274)		$ (15,031)		$ (14,027)		$ (13,708)		$ (10,878)		$ (59,384)	$ (53,644)	$ (23,918)
Denominator:
Weighted-average shares of common stock used to compute net loss per share attributable to common stockholders, basic and diluted (in shares)																		21,076,246	12,482,988	12,044,447
Dilutive effect of stock options, warrants, and restricted stock units (in shares)	[1]																	0	0	0
Net loss per share attributable to common stockholders, basic and diluted (in usd per share)		$ (0.53)	[2]	$ (0.47)	[2]	$ (1.01)	[2]	$ (1)	[2]	$ (1.10)	[2]	$ (1.16)	[2]	$ (1.13)	[2]	$ (0.90)	[2]	$ (2.82)	$ (4.30)	$ (1.99)
[1]	Potentially dilutive stock options, warrants, and restricted stock were excluded from the calculation of diluted weighted-average shares outstanding as they would have had an anti-dilutive effect due to losses reported during the years ended December 31, 2015, 2014, and 2013.
[2]	Net loss per share is calculated independently for each quarter presented. Therefore, the sum of the quarterly net loss per share amounts will not necessarily equal the total for the year.

Net Loss per Common Share (De63

Net Loss per Common Share (Details 2) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from EPS (in shares)	1,936,254	528,506	395,587
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from EPS (in shares)	848,400	341,345	391,526
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from EPS (in shares)	4,061	187,161	4,061
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from EPS (in shares)	1,083,793	0	0

Income Taxes Net Loss Before In

Income Taxes Net Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest	$ (59,745)	$ (52,728)	$ (25,476)
Domestic Tax Authority [Member]
Income Tax Contingency [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest	(57,726)	(57,444)	(14,458)
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest	$ (2,019)	$ 4,716	$ (11,018)

Income Taxes (Expense) Benefit

Income Taxes (Expense) Benefit Attributable To Net Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
U.S. federal, Current	$ 0	$ 0	$ 0
U.S. federal, Deferred	0	0	0
U.S. federal, Total	0	0	0
State and local, Current	(13)	(8)	(38)
State and local, Deferred	0	0	0
State and local, Total	(13)	(8)	(38)
Foreign jurisdiction, Current	0	(18)	0
Foreign jurisdiction, Deferred	374	(890)	1,596
Foreign jurisdiction, Total	374	(908)	1,596
Total, Current	(13)	(26)	(38)
Total, Deferred	374	(890)	1,596
Total	$ 361	$ (916)	$ 1,558

Income Taxes Effective Income T

Income Taxes Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Tax at statutory rate	34.00%	34.00%	34.00%
State taxes	10.64%	2.64%	1.55%
Other/permanent items	(2.63%)	(0.28%)	(2.58%)
Foreign rate differential	(0.22%)	0.60%	(2.81%)
Change in valuation allowance	(41.19%)	(38.68%)	(23.96%)
Effective tax rate	0.60%	(1.72%)	6.20%

Income Taxes Deferred Tax Asset

Income Taxes Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Accounts receivable, principally due to allowance for doubtful accounts	$ 334	$ 310
Inventories	521	370
Compensated absences, principally due to accrual for financial reporting purposes	244	300
Compensated bonuses, principally due to accrual for financial reporting purposes	465	411
Net operating loss carryforwards	52,065	30,465
Property and equipment, principally due to differences in depreciation	1,519	875
Other	1,311	658
Total gross deferred tax assets	56,459	33,389
Less valuation allowance	(55,842)	(32,212)
Net deferred tax assets	617	1,177
Deferred tax liabilities:
Intangibles	(3,110)	(4,038)
Other	0	(316)
Total gross deferred liabilities	(3,110)	(4,354)
Net deferred tax liability	$ (2,493)	$ (3,177)

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Tax Contingency [Line Items]
Deferred income taxes	$ 0	$ 970,000
Non-current deferred tax assets		207,000
Deferred income taxes	3,110,000	4,354,000
Valuation allowance	(55,842,000)	(32,212,000)
Liability for uncertain tax positions	0	$ 0
Domestic Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating loss carryforwards	124,822,000
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating loss carryforwards	128,730,000
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating loss carryforwards	$ 5,422,000

Segment, Geographical, and Cu69

Segment, Geographical, and Customer Concentration (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)segment	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment									1
Net revenues	$ 18,547	$ 18,363	$ 18,642	$ 16,748	$ 18,322	$ 14,169	$ 15,081	$ 13,847	$ 72,300	$ 61,419	$ 50,891
Long-Lived Assets	45,447				46,624				45,447	46,624
UNITED STATES [Member] | Reportable Geographical Components [Member]
Segment Reporting Information [Line Items]
Net revenues									64,675	54,570	45,457
Long-Lived Assets	7,694				6,516				7,694	6,516
Non-US [Member] | Reportable Geographical Components [Member]
Segment Reporting Information [Line Items]
Net revenues									7,625	6,849	$ 5,434
ISRAEL [Member] | Reportable Geographical Components [Member]
Segment Reporting Information [Line Items]
Long-Lived Assets	31,694				33,855				31,694	33,855
Other Regions [Member] | Reportable Geographical Components [Member]
Segment Reporting Information [Line Items]
Long-Lived Assets	$ 6,059				$ 6,253				$ 6,059	$ 6,253

Retirement Plans (Details)

Retirement Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
United States Postretirement Benefit Plan of US Entity [Member] | 401(k) Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions	$ 0	$ 0	$ 0
Foreign Postretirement Benefit Plan [Member] | Severance Pay Funds And Insurance Policies [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions	987,000	802,000	360,000
Foreign Postretirement Benefit Plan [Member] | Discretionary Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions	20,000	2,000	5,000
Foreign Pension Plan [Member] | German Retirement Plans [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions	$ 0	$ 5,000	$ 3,000

Selected Quarterly Financial 71

Selected Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																12 Months Ended
	Dec. 31, 2015		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 18,547		$ 18,363		$ 18,642		$ 16,748		$ 18,322		$ 14,169		$ 15,081		$ 13,847		$ 72,300	$ 61,419	$ 50,891
Gross profit	5,057		6,141		6,533		5,579		5,035		5,791		5,291		6,394		23,310	22,511	24,999
Operating loss	(12,538)		(10,443)		(14,824)		(12,451)		(12,801)		(11,710)		(12,566)		(10,138)		(50,256)	(47,215)	(25,699)
Net loss	$ (13,045)		$ (11,578)		$ (19,487)		$ (15,274)		$ (15,031)		$ (14,027)		$ (13,708)		$ (10,878)		$ (59,384)	$ (53,644)	$ (23,918)
Net loss per share attributable to common stockholders, basic and diluted (in usd per share)	$ (0.53)	[1]	$ (0.47)	[1]	$ (1.01)	[1]	$ (1)	[1]	$ (1.10)	[1]	$ (1.16)	[1]	$ (1.13)	[1]	$ (0.90)	[1]	$ (2.82)	$ (4.30)	$ (1.99)
[1]	Net loss per share is calculated independently for each quarter presented. Therefore, the sum of the quarterly net loss per share amounts will not necessarily equal the total for the year.

Schedule II - Valuation and Q72

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances beginning balance	$ 860	$ 1,040	$ 315
Additions	979	466	992
Deductions	(899)	(646)	(267)
Valuation Allowances ending balance	940	860	1,040
Deferred income tax valuation allowance [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances beginning balance	32,212	12,004	5,653
Additions	23,630	20,208	6,351
Deductions	0	0	0
Valuation Allowances ending balance	$ 55,842	$ 32,212	$ 12,004